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Summary 
Liver stage development is the first obligate replication phase of the malarial para-
site Plasmodium in the mammalian host. Rapid intracellular growth and differenti-
ation of a single parasite in the hepatocyte result in release of thousands of patho-
genic blood-stage merozoites. Parasite-host interactions during this clinically silent 
pre-erythrocytic phase and their roles in disease outcome of Plasmodium infections 
remain largely unknown.  
It was previously shown that essential parasite-encoded proteins at the patho-
gen/host interface cooperate with host proteins, such as apolipoprotein A1 (APOA1), 
Fatty Acid Binding Protein (FABP1) and SNAP-associated Protein (SNAPAP), in the 
liver.  
In my study I used high-density screening of genetic variants in patient cohorts in a 
malaria-endemic area to examine the influence of genetic variations in the genes, 
coding for these liver stage ligands, on P. falciparum incidence and disease out-
come.  
My results revealed that a single nucleotide polymorphism (SNP) rs670 (G/A) in the 
5’ untranslated region of human APOA1 affects both incidence and outcome of P. 
falciparum malaria. Non-immune children below 5 years carrying the G allele had a 
50% lower risk of re-infections and significantly reduced odds of severe malaria. It is 
well documented that the sickle cell trait (HbAS) and other established polymorph-
isms protect against disease caused by pathogenic Plasmodium blood stages. Fur-
ther, I performed in vitro experiments that suggest an enhanced development of P. 
berghei late liver cell stages due to high level of APOA1. 
In this study, I establish that additional selection for alleles affecting pre-erythrocytic 
parasite development may play previously unrecognised roles in malaria disease 
outcome. My results verify the relevance of clinically silent pathogen expansion 
phases, such as maturation of Plasmodium liver stages, for the clinical epidemiology 
of infectious diseases. 
 
 
 
 
 
  
2 
Zusammenfassung 
Das Leberzellstadium ist die erste notwendige Replikationsphase des Plasmodium-
Parasiten im Säugetier. Schnelles intrazelluläres Wachstum und Ausdifferenzierung 
eines einzelnen Parasiten in der Leberzelle führt zur Freisetzung von tausenden 
Merozoiten, die anschließend Erythrozyten infizieren. Interaktionen zwischen Parasit 
und Wirt während dieser klinisch unauffälligen Phase sind größtenteils unbekannt. 
Es wurde gezeigt, dass lebenswichtige Proteine des Parasiten mit Proteinen des 
Wirts, wie Apolipoprotein A1 (APOA1), Fatty Acid Binding Protein (FABP1) und 
SNAP-assozierten Protein (SNAPAP), kooperieren.  
In meiner Studie untersuchte ich in Patienten aus malaria-endemischen Gebieten 
genetische Varianten in den drei Genen, die diese Leberstadien-spezifischen Ligan-
den kodieren, und analysierte ihren Einfluss auf die Häufigkeit von P. falciparum 
Infektionen und den Krankheitsverlauf.  
Meine Ergebnisse zeigen, dass der Einzelnukleotidpolymorphismus rs670 (G/A), im 
5’ untranslatierten Bereich von APOA1, die Häufigkeit und den Ausgang von P. fal-
ciparum Malaria beeinflusst. Nicht immune Kinder unter 5 Jahren, die das G Allel 
haben, hatten ein 50% geringeres Risiko einer Reinfektion und eine signifikant re-
duziertes Risiko für schwere Malaria. Es ist beschrieben, dass genetische Eigen-
schaften wie Sichelzellanämie (HbAS) und andere Varianten vor Komplikationen 
schützen, die durch P. falciparum Blutstadien ausgelöst werden. Zusätzliche in vitro 
Experimente lassen auf eine verbesserte Entwicklung von späten P. berghei Leber-
stadien durch APOA1 schließen. 
In dieser Studie zeige ich, dass zusätzliche Selektion von Allelen, die einen Einfluss 
auf die prä-erythrozytäre Parasitenentwicklung haben, eine Rolle im Krankheitsver-
lauf von Malaria spielen können, die bisher unbekannt war. Meine Ergebnisse be-
stätigen die Relevanz von klinisch unauffälligen Wachstumsphasen, wie die Reifung 
der Plasmodium Leberstadien, für die klinische Epidemiologie von Infektionskrank-
heiten. 
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1.  Introduction 
 
1.1  Malaria: past and present 
Historical records of seasonal fevers associated with marshes and biting insects 
exist in different cultures like the ancient Chinese, Indians and Assyrians. In the 5th 
century BC Hippocrates (460-370 BC) observed a connection between appearance 
of disease and seasons of the year and described the clinical picture of malaria. 
Celsus (25 BC-54 AD) portrayed a detailed picture of various types of malaria. In the 
18 century the people related these typical fevers to the foul air near swamps and 
therefore it was widely named as malaria from the Italian “mala aria”.  
In 1880 the army surgeon A. Laveran (1845-1922) first described malaria parasites 
in human blood. Around ten years later D.L. Romanowski (1861-1921) developed a 
polychrome staining method for demonstrating plasmodia in blood smears. The 
transmission was still unresolved until Sir Patrick Manson (1844-1922) proposed a 
transmission from person to person by mosquitoes in 1894. His theory was sup-
ported by Sir Ronald Ross’ (1857-1932) findings of pigmented cysts in Anopheles 
mosquitoes in 1897. A year later Ross worked out the complete cycle of bird ma-
laria. In 1898 G. Grassi (1854-1925), A. Bignami (1861-1919) and G. Bastianelly 
(1862-1959) in Italy described the cycle of human malaria parasites. Rossʼ work 
earned him the 1902 Nobel Prize in medicine. 
Until now more than 120 Plasmodium species were identified of which P. falciparum, 
P. vivax, P. knowlesi, P. ovale and P. malariae are able to infect human hosts. In the 
past malaria was widely distributed around the world. Records of indigenous malaria 
reached from Russia down to Argentina (Hay et al., 2004). In these endemic areas 
malaria free regions were found because of environmental factors limiting the 
transmission. From the Middle Ages until last century parts of Europe and North 
America were endemic areas. In the 1950s it was eradicated from North America 
and in the 1960s from Southern Europe.  
Today malaria is one of the most important health burdens and reason of child mor-
tality worldwide. P. falciparum causes about half a billion episodes of disease and 
kills 1 to 2 million children in Africa annually (Snow et al., 2005). Other less lethal 
species P. vivax, P. ovale and P. malariae are responsible for additional hundreds of 
million cases. 
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Worldwide 1.38 billion people are at risk of P. falciparum malaria: 0.69 billion in 
Central and South East Asia, 0.66 billion in Africa, Yemen, and Saudi Arabia, and 
0.04 billion in Middle and South America (Hay et al., 2009). These areas differ by 
the level of P. falciparum endemicity and transmission intensities (Figure 1). Uni-
formly low endemic levels are found from Middle to South America. Low endemicity 
of P. falciparum malaria is widespread in Asia with small areas of intermediate and 
very rarely high transmission. High levels of endemicity are common in Africa 
whereas P. vivax occurs mainly outside of Africa in tropical and sub-tropical regions. 
In areas where both species co-exist mixed infections are common (Snounou and 
White, 2004). 
The health- and socio-economic impact of P. falciparum malaria is highest in Sub-
Saharan Africa. 70% of all cases and 75% of all mortality cases are in children 
younger than five years were concentrated in this region (Snow et al., 2005; Bre-
man, 2001). The high death toll and continuous health burden affects the economic 
growth in endemic areas. The impact on local economy includes costs of health 
care, working days lost due to sickness, days lost in education, decreased produc-
tivity due to brain damage from cerebral malaria, and loss of investment and tourism 
(Greenwood et al., 2005). Gallup and Sachs (2001) described that the level of gross 
national product per capita in a malarious country is reduced to more than half of 
that of a non-malarious country. Therefore, the fight against malaria was set as a 
main goal to reduce extreme poverty in these regions at the Millennium Summit in 
September 2000. 
 
Figure 1: The spatial distribution of P. falciparum malaria endemicity 
Annual P. falciparum parasite rates (PfPR) in children from 2-10 years within the 
stable spatial limits of transmission (yellow to red, 0%–100%). The rest of the land 
area was defined as unstable risk (dark grey). (Hay et al., 2009). 
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1.2  Characteristics of Plasmodium 
Plasmodium parasites are protozoa of the genus Plasmodium. Genealogically they 
are organized in the phylum of Apicomplexa, class of Sporozoa, order of Coccidia, 
suborder of Haemosporidiae and family of Plasmodiiae.  
Plasmodium parasites are found in a spectrum of hosts like mammals, reptiles and 
birds. The great majority of the parasites are transmitted by various mosquito spe-
cies whereas human malaria parasites are exclusively transmitted by anophelines. 
All Plasmodium species show strong host specificity. The believed last common 
ancestor with a two-host life cycle in Dipterans and vertebrates that evolved around 
130 million years ago indicates a long history of co-adaption between host and 
parasite (Carter and Mendis 2002).  
The life cycle of Plasmodium is complex and depends on 2 hosts. Therefore, the 
parasite must adapt to different environmental and host specific conditions and fac-
tors. All mammalian Plasmodium species have comparable life cycles. The sexual 
stage is linked to the invertebrate host whereas the asexual stage only occurs in the 
mammal.  
The parasite in its sporozoite form is injected into the host by the female mosquito 
during the blood meal. After short inoculation times the sporozoites enter the blood-
stream and finally invade hepatocytes. Liver resident macrophages, so called Kup-
ffer cells, serve as gateways for sporozoites to enter the hepatocytes (Frevert, 
2004). Immediately after invasion the parasitophorous vacuole membrane (PVM) 
forms around the sporozoite. The liver stage undergoes nuclear replication and ma-
tures to hepatic schizonts (Amino et al., 2006, Vaughan et al., 2008). These liver cell 
stages release thousands of merozoites in the blood stream surrounded by host cell 
membrane, so called merosomes (Sturm et al., 2006). In a rodent model the ma-
jority of merosomes exit the liver intact and accumulate in the lungs, where the 
merozoites are released (Baer et al., 2007). P. vivax and P. ovale liver cell stages 
are exceptional because some can arrest their development and form hypnozoites.  
 
Released merozoites are capable to infect erythrocytes. After invasion a PVM forms 
around the merozoite. At first, it differentiates into a ring trophozoite and then into a 
mature throphozoite that enlarges to form a schizont and finally divides into intra-
erythrocytic merozoites until the multiplying parasite causes the infected red blood 
cell to rupture and release of a new generation of merozoites (Cowman and Crabb, 
Introduction 
 
 
6 
2006). The duration of this phase differs between different Plasmodium species and 
strains, typically 48 hours for P. falciparum, vivax and ovale or 72 hours for P. ma-
lariae. Upon erythrocyte infection, some merozoites differentiate into sexual forms, 
so-called gametocytes. The male gametocytes undergo a rapid nuclear division if a 
female mosquito takes them up via blood meal. Their nucleus divides into four to 
eight nuclei that exflagellate. These so called microgametes fertilize the female 
macrogametes. The resulting ookinete penetrates the midgut wall and transforms 
under the midgutʼs basal membrane into an oocyst. After rupture of the mature 
oocyst more than 1,000 sporozoites are released and some invade the mosquitoʼs 
salivary glands via the haemolymph. They can be transmitted into a susceptible host 
via the saliva during the mosquitoʼs next blood meal and complete the life cycle. 
 
 
 
 
 
 
 
Figure 2: Life cycle of human Plasmodium 
Details described in the text (www.dpd.cdc.gov). 
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1.3  Clinical features of malaria 
Malaria is an acute febrile illness. Disease outcome depends on species of parasite, 
age, genetic factors, nutritional status, state of health and immunity of the patient. 
After infection the liver cell stage is clinical silent.  
The first clinical sign is fever followed by febrile paroxysms. 2 to 3 days before the 
first paroxysm patients often complain of malaise, headache, dizziness, fatigue, 
pain, anorexia and nausea. The paroxysms are divided into three stages: the cold 
stage (shivering), the hot stage (fever) and the sweating stage with subsequent de-
clining fever. The paroxysms periods repeat every 48 or 72 hours in dependence of 
the Plasmodium species. Due to these patterns malaria was given its other names: 
Benign tertian malaria (P. vivax), malignant tertian (P. falciparum), tertian (P. vivax, 
P. ovale) and quartan malaria (P. malariae). It only occurs with a synchronized 
parasite population in the patient. In P. falciaprum malaria the periodicity is often not 
clearly defined resulting in continuous or remittent fever in patients.  
In non-immune patients, the disease can rapidly progress to life-threatening severe 
malaria, which is caused by sequestration in different organs and host immune re-
sponses (Mackintosh et al., 2004). Severe malaria can develop into a complex multi-
system disorder, which is characterized by cerebral malaria, hepatic dysfunction, 
anaemia, renal dysfunction, pulmonary oedema, metabolic acidosis, hypoglycaemia, 
circulatory collapse and/ or coma (Rasti et al., 2004).  
Malaria during pregnancy can result in anaemia in the pregnant woman, low birth 
weight, premature birth, abortion and increased perinatal death. The risk for the 
woman is highest at the first pregnancy and diminishes in subsequent pregnancies 
(Andrews and Lanzer, 2002).  The severity of disease is determined by a combina-
tion of parasite virulence factors and host inflammatory responses (Mackintosh et 
al., 2004). 
 
 
1.4  Immunology of malaria 
The clinical outcome of a malaria infection depends on many factors. Besides key 
influences from host and parasite, the transmission dynamics of the disease play an 
important role (Baird et al., 1998). In regions with stable year-round Plasmodium 
transmission by infected mosquito bites exist a persistent level of low parasitaemia 
in the population. Only a small percentage of the infected patients develop severe 
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malaria. All clinical outcomes can be observed but the majority shows no or only 
mild clinical symptoms. Populations in low transmission areas have a higher risk of 
severe complications per infection. Stable transmission seems to play a major role 
in development of immunity against malaria (Mbogo et al. 1995, Snow et al. 1997). 
Acquisition of immunity is a slow process. Even in high transmission areas it takes 
years and only leads to clinical protection but not sterile immunity against the para-
site (Gilles and Warrell, 2002). In high-transmission areas malaria is a severe threat 
for children from 0 to 5 years but a mild condition in adults (Baird et al., 1998). Se-
verity of malaria declines from the 4th year and one-year later death is a scarce dis-
ease outcome. A substantial immunity can be already acquired with 1 or 2 episodes 
of malaria (Gutpa et al., 1999). In adults mild symptoms like fever and headache are 
common disease outcomes. However, all age groups are still susceptible to Plas-
modium infections and parasite prevalence is high. In regions with unstable malaria 
transmission the acquisition of immunity is delayed. Moreover, immunity appears not 
to be stable.  
 
 
 
 
 
 
Figure 3: Population indices of immunity to P. falciparum. 
The age pattern of asymptomatic parasite prevalence and the period prevalence of both 
mild and severe clinical malaria are shown in relation to maximum prevalences recorded 
from studies in Kilifi at the Kenyan coast (Marsh and Kinyanjui, 2006). 
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Plasmodium is a complex organism with different morphological forms in the human 
host. Accordingly, the host immune response is confronted by intra- and extracellu-
lar parasites with thousands of recognizable epitopes. Immunity is first acquired 
against life-threatening disease, then later against symptomatic infection and finally 
partial immunity to parasitaemia (Schofield and Grau, 2005). Immunity to malaria 
consists of cellular and humoral responses against all stages of infection. Antibodies 
play an important role against extracellular Plasmodium forms. It was shown that 
they could immobilize sporozoites inoculated in the skin (Vanderberg and Frevert, 
2004) or block host cell invasion of merozoites (Cohen and Butcher 1970). Against 
intra-hepatocytic Plasmodium stages interferon-γ (IFN- γ), CD4+ T cells and CD8+ 
T-cell responses are key factors (Stevenson and Riley, 2004; Doolan and Martinez- 
Alier 2006). Details to immune responses at different P. falciparum life stages are 
described in Figure 4. 
Until today a major hope to fight and finally eradicate malaria is the development of 
a malaria vaccine. However, an affordable and effective vaccine has not been found 
yet. Different vaccine approaches targeting pre-erythrocytic, erythrocytic and trans-
mission phase of Plasmodium are in development.  
Nussenzweig et al. (1967) have demonstrated that a short-lived protection against 
malaria can be achieved by vaccination with irradiated sporozoites. Immunization 
with radiation-attenuated sporozoites (RAS) could be induced in rodents, non-
human primates and humans nevertheless their deployment in endemic areas was 
not possible yet (Doolan and Hoffman, 2000; Ballou, 2007). 
As a metabolic center, the liver plays an important role in carbohydrate and lipid 
metabolism, glycogen storage, plasma protein synthesis, hormone production, bile 
formation, detoxification and breakdown of compounds. Compared with other or-
gans, the liver is particularly enriched with cells of the innate immune system and 
antigens from the gastrointestinal tract first encounter the innate immune system 
defences there (Mehal et al., 2001). Accordingly, strategies against liver cell stages 
are suggested as a key vaccine target. Blocking sporozoite invasion into the liver by 
antibodies or elimination of liver cell stages by Cytotoxic T lymphocytes (CTLs) 
would lead to a sterile protection.  
A vaccination with living Plasmodium sporozoites that are able to invade hepato-
cytes, but do not replicate due to radiation-, genetic or chemical attenuation are 
promising approaches against an extreme complex parasite like Plasmodium (Luke 
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and Hoffman, 2003; Mueller et al., 2005 (1,2); Jobe et al., 2007; Purcell et al., 2008).  
Another liver-stage–based strategy is a recombinant vaccine, called RTS,S/AS01 
consisting of the P. falciparum circumsporozoite protein (CSP) found on the surface 
of the sporozoite. Due to its low immunogenic capacity it is fused with a hepatitis B 
surface antigen formulated in an adjuvant system for a higher immune response 
(Ballou, 2009). Until now, it seems to be the only out of 47 candidates that reach 
phase III (Langhorne et al., 2008). 
 
 
Figure 4: P. falciparum life cycle with host immune responses. 
Top left and right: plasmodia that infect humans and rodents. Numbers indicate effector 
mechanisms thought to be effective against Plasmodium in the mammalian host and in 
blocking transmission to the mosquito: 1: antibodies to sporozoites neutralize sporozoi-
tes and/or block invasion of hepatocytes; 2: IFN- and CD8+ T cells (CD4+ dependent), 
natural killer (NK) cells, natural killer T (NKT) and T cells kill intrahepatic parasites; 3: 
antibodies to merozoites opsonize merozoites for uptake and/or inhibit invasion of 
RBCs; 4: antibodies to infected RBCs surface opsonize infected RBCs for phagocytosis 
and/or block the adhesion of infected RBCs to endothelium; TNF and IFN-γ  activate 
macrophages to phagocytose and/or kill infected RBCs and merozoites; antibodies to 
glycosylphosphatidylinositol neutralize parasite toxins and prevent the induction of ex-
cessive inflammation; 5: antibodies to infected RBCs prevent the sequestration of ga-
metocytes, which prevents the sequestration and maturation of gametocytes; 6: anti-
body and complement taken up in the blood meal mediate the lysis of gametocytes and 
prevent fertilization and further development of the parasite in the mosquito. ROI, reac-
tive oxygen intermediate; NO, nitrous oxide. Fever and severe malaria are associated 
with the parasite cycle in the blood, as well as rosetting of infected RBCs to blood ves-
sel endothelium (blue insert) (Langhorne et al., 2008). 
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1.5  Hepatocyte stage proteins and host-parasite interactions 
Until now, very little is known about the molecular mechanisms of invasion and de-
velopment of liver cell stages. The PVM acts as barrier between the parasite and the 
host cell but also as a gateway for interactions. A functional PVM is required for liver 
cell stage development and final maturation to merozoites. This was supported by a 
double knock-out mutant of P. yoelii that was unable to form a stable PVM (Labaied 
et al., 2007). 
So far, several essential interactions between the host hepatocyte and the parasite 
could be observed in rodent models. Silvie et al. (2008) identified an asparagine rich 
protein named “sporozoite and liver stage asparagin-rich protein“ (SLARP) that is 
only expressed in sporozoites and liver cell stages. P. yoelii SLARP knock-out ex-
periments showed a normal invasion but an impaired development in the liver. Ma-
tuschewski et al. (2002) identified 2 proteins, referred as “Upregulated in infective 
sporozoites gene” (UIS) 3 and 4, which are exclusively expressed in the liver cell 
stage of P. berghei. These proteins, members of the “early transcribed membrane 
proteins” (ETRAMP) family are located in the PV tubovesicular network with their C-
terminal ends in the hepatocyte’s cytoplasma (Spielmann et al., 2006 1).  
Uis3 and uis4 knock-out mutants showed an impaired development and failed finally 
in establishing a blood infection in mice. Located in the PVM, both proteins interact 
with host ligands like Apolipoprotein A1 (APOA1) and Fatty Acid Binding Protein 1 
(FABP1), which were identified in a yeast-two hybrid screen (Mueller, personal 
communication). A third ligand, SNAP Associated Protein (SNAPAP), was found 
interacting with UIS7, which contrary to UIS3 or UIS4 has no homolog in P. falcipa-
rum (Mueller Ak, unpublished). A reverse immunization with uis3- and uis4-deficient 
sporozoites conferred complete protection against infectious sporozoite challenge in 
a rodent malaria model. 
 
Both, APOA1 and FABP1, are involved in the lipid metabolism of the host. Mainly 
expressed in the liver FABP1 is the key player in the lipid composition of the liver 
(Fisher et al., 2007).  This small, highly conserved, cytoplasmic protein is able to 
bind long-chain fatty acids, bile acids and other hydrophobic ligands. An essential 
interaction between FABP1 and P. yoelii liver cell stages could be demonstrated by 
Mikolajczak et al. (2007). In humans a coding SNP in FABP1 was associated with 
fasting triglycerides and LDL-cholesterol concentrations in women (Fisher et al., 
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2007). 
The conserved APOA1 is the major protein component of high-density lipoprotein 
(HDL) in plasma, which transports cholesterol from tissues to the liver for excretion. 
It is a cofactor for lecithin cholesterolacyltransferase (LCAT), which is responsible 
for the formation of most plasma cholesteryl esters. Several diseases or beneficial 
effects are linked to variation in APOA1. Amyloidosis (Soutar et al. 1992), hypertri-
glyceridemia (Stocks et al., 1987), dyslipoproteinemia (Strobl et al., 1988) and many 
more diseases are influenced by APOA1. The best-known protective effect of 
APOA1 is against cardiovascular diseases (Ajees et al., 2006). Recently, a complex 
of APOA1, apolipoprotein L-1 (apoL1) and haptoglobin-related protein (Hpr) was 
observed in killing trypanosomes through anionic pore formation in the lysosomal 
membrane of the parasite (Paysa and Vanhollebeke, 2009; Harrington et al., 2009).  
SNAPAP, a small protein of 139 residues, is component of the SNARE complex of 
proteins that is required for synaptic vesicle docking and fusion (Ilardi et al., 1999). 
Its function is not clear but it has been shown that it interacts with SNAP-25, BLOC-
1, SNAP23, Dysbindin, TRPV1, PLDN and RGS7 (Starcevic and Dell'Angelica, 
2003; Hunt et al., 2003; Morenilla-Palao et al., 2006). 
 
The role of lipids for Plasmodium remains unclear. It is hypothesized that the fast 
development of the parasite in the liver requires a high amount of lipids and thus 
interaction with lipid carriers of the host is essential (Mikolajczak et al., 2007). A 
change in serum lipid and lipoprotein compositions in the patients due to Plas-
modium infections was observed (Blair et al. 2002; Faucher et al. 2002). In malaria-
exposed primigravidae APOA1 plasma level in are associated with severe malaria 
(Simpson et al., 2010). Because of high demand for lipids Mitamura and Palacpac 
(2003) proposed the lipid metabolism as an attractive target for anti-malarial drugs.  
 
Initially, it was thought that Plasmodium was incapable of fatty acid de novo synthe-
sis but components of type II fatty acid biosynthesis (FAS-II) pathway were discov-
ered (Ralph et al., 2004). Localized in the apicoplast it was shown that FAS-II is es-
sential for malaria parasite late liver stage development (Vaughan et al., 2009). In 
contrast to the related Toxoplasma gondii that depends on LDL (Sehgal et al., 2005) 
lipid trafficking between HDL and Plasmodium falciparum-infected red blood cells 
was observed (Grellier et al., 1991).  
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In liver cell stages cholesterol seems to play a major role (Rodrigues et al. 2008). A 
disruption of the host cell receptor “scavenger-receptor-BI“ (SR-BI) showed a nega-
tive impact on liver stage development (Yalaoui et al., 2008). SR-BI is a high-affinity 
HDL receptor that plays a role in lipid concentration in the plasma (Trigatti et al., 
2003, Masson et al., 2009). Moreover, HDL/SR-BI interaction with CD81 seems to 
influence infectivity of the host cell to hepatitis C or Plasmodium (Rodrigues et al., 
2008; Yalaoui et al., 2008; Dreux et al., 2009). 
 
 
1.6  Genetic host factors influencing protection against malaria 
Plasmodium is highly adapted to its hosts. In the whole life cycle the parasite de-
pends on specific interactions with the host for access to nutrients, overcome phys-
ical barriers or avoidance of immune responses. On all stages the parasite is sus-
ceptible to interruptions leading to a reduced survival of the parasites and an in-
creased fitness for the exposed host. The genetic basis of resistance to malaria is 
complex and probably many unknown genes are involved. Until now, several human 
genetic traits have been identified that effect susceptibility to and/ or pathogenesis of 
P. falciparum malaria. These are shown to affect resistance to malaria, disease ou-
come and the immune response of the host (Kwiatkowski, 2005). An overview of 
host factors associated to malaria and their characteristics are listed in table 1 (a,b 
and c). 
 
The best-described example for genetically induced protection is the HBB gene. 
Three different single nucleotide polymorphisms (SNPs) confer protection against 
malaria by amino acid substitution: Glu6Val (HbS), Glu6Lys (HbC) and Glu26Lys 
(HbE). Structurally each haemoglobin molecule consists of a haeme molecule sur-
rounded by four polypeptide chains referred to as α- and β-globins. All substitutions 
result in alterations of the β-chain of the haemoglobin molecule. β-thalassaemia 
mutations in the HBB gene lead to either complete loss of function or production of 
low levels of the β-globin protein. 
The red blood cells of HBB S heterozygotes, so-called sickle cell trait (HbAS), carry 
a normal and an abnormal β-chain with an unobtrusive phenotype under normal 
conditions. Homozygotes’ (HbSS) erythrocytes show under hypoxia an abnormal 
sickle shape as a result of 2 abnormal β-chains. Sickle cell disease has a poor 
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prognosis and, if untreated, can be fatal in early childhood. In spite of homozygote 
mortality, the HBB S allele is found in increased frequencies over 20% in malaria-
endemic areas compared to malaria free regions (Kwiatkowski, 2005). Due to a 90% 
reduced risk of severe malaria the polymorphism is an example for balanced selec-
tion where the deleterious effects of the HbSS genotype prevent the S allele’s fix-
ation (Williams et al., 2005; Kwiatkowski, 2005). The other variants of the HBB 
gene—namely, HbC and HbE or beta thalassaemia show only mild clinical symp-
toms (Stuart and Nagel, 2004).  
Variations in the HBA gene, causing α-thalassaemia, are affecting risk of malaria as 
well. Deletion of one or both α-globin genes due to a mutation in HBA results in an 
autosomal recessive disease. In Africa the most common is the heterozygous α-- 
and homozygous α+–thalassaemia trait. Because of the malaria-protective character 
and the absence of strong negative effects on health, the allele frequencies have 
risen to high frequencies (up to 80%) in many populations (Williams, 2006). Indi-
viduals with α+–thalassaemia are usually asymptomatic except for occasional mild 
anaemia and low red blood cell indices.  
Mechanisms of protection afforded by Hb variants remain largely unknown. For HbS 
two mechanisms are hypothesized: The suppression of parasite growth in red cells 
and enhanced splenic clearance of parasitized erythrocytes (Kwiatkowski, 2005).  
Both, difficult to examine in vivo, is supported by a reduced incidence of clinical ma-
laria and lower parasite densities observed in children with HbAS (Williams et al. 
2005 (2)). Furthermore, HbS seems to have a synergistic effect on acquired im-
munity: Williams et al. (2005, 1) observed an increased malaria-protective effect in 
2-10 years old Kenyan children.  
Like for sickle cell, the protective mechanisms of α-thalassemia are largely un-
known. Pattanapanyasat et al. (1999) showed a reduced parasite growth in erythro-
cytes expressing the a+-thalassaemia phenotype. Other in vitro studies support dif-
ferent mechanisms like an impaired ability to form rosettes, better splenic clearance, 
reduced expression of complement factor 1 (CR1) and higher expression of anti-
gens in infected erythrocytes (Williams, 2006). However, both α-- and α+–
thalassaemia protect against severe and fatal malaria but has no effect either on 
mild or rather symptomless malaria or parasite densities in the blood (Williams et al., 
2005, 3 and 2006). All of these genetic polymorphisms could influence each other 
and thus susceptibility to malaria and disease outcome. Indeed, Wiiliams et al. 
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(2005, 3) observed a negative epistasis between the malaria-protective effects of 
a+-thalassemia and the sickle cell trait. The incidence of mild and severe falciparum 
malaria was close to baseline if both phenotypes were inherited together. 
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1.7  Effects of evolutionary selection on the human genome by malaria 
Malaria was one of the most driving forces in history of mankind. With the introduc-
tion of agriculture, settlement and thus growing population size, malaria gained in 
importance at beginning of the Neolithic period around 10,000 years ago. The high 
mortality and morbidity of malaria especially of P. falciparum applied a strong selec-
tive pressure on the human genome (Klein and Takahata, 2002; Kwiatkowski, 
2005). In recent years an increasing number of identified human genes affecting 
malaria bear witness of the strong influence of Plasmodium in history of humankind. 
The heritability of malaria susceptibility was shown in Gambia by Jepson et al. 
(1997). They observed a higher chance of malaria fever attacks in monozygotic than 
in dizygotic twins. In two cohort studies in Kenyan children it was found that 25% of 
the total variation in incidence of mild clinical malaria and hospital admissions to 
malaria was explained by additively acting host genes. HbAS, the strongest known 
resistance genetic factor explained only 2% suggesting the existence of many un-
identified malaria-protective genes (MacKinnon et al., 2005). 
Adaptations to malaria can have disadvantageous effects like the high mortality of 
HbSS or the thalassemias. They are the most common Mendelian diseases of hu-
mans and they constitute a major global health problem today. About 75% of the 
global haemoglobinopathies occur in sub-Saharan Africa with more than 200,000 
affected newborns per year (Weatherall and Clegg, 2001).  
 
Inter-ethnic comparisons of susceptibility to malaria show that different malaria-
resistance alleles have arisen in different places. Human population diversity in 
Africa is exemplified by over 2,000 distinct ethnic groups. Recent studies observed 
extensive genetic variation among even geographically close African populations 
(Tishkoff and Williams, 2002; Tishkoff et al., 2009). For example the HBB S allele is 
common in Africa but rare in Southeast Asia, whereas the opposite is true for the 
HBB E. In West Africa HBB C is more frequent than the HBB S allele (Kwiatkowski, 
2005). Other different geographic distributions of genetic traits like of the thalassae-
mias, glucose-6-phosphate dehydrogenase (G6PD) deficiency or the Duffy-negative 
blood group support the theory that they evolved in different populations. Moreover, 
it seems that the same genotype has arisen several times independently in different 
populations like HbS that is found in 4 different haplotypes (Lapouméroulie et al., 
1992) or the geographic allele diversity of G6PD (Tishkoff et al., 2006). 
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1.8  Association studies and signatures of selection 
The idea that malaria has been acting as a major evolutionary force in recent human 
history has driven the development of tools to explore the human genome for signa-
tures of positive selection (Sabeti et al, 2006). Identifications of the proposed candi-
dates for selection, like HBB S in Africa or lactase (LCT) in Europe, have strong 
functional support because due to the direct influence of the mutation on the pheno-
type. Most proposed candidates lack compelling biological evidence and are only 
relied on comparative and population genetic evidences (Sabeti et al., 2006). Well-
defined phenotypes, one or two genetic disease loci with a high penetrance, a small 
phenocopy rate and usually small allele frequencies characterize Mendelian traits 
that are rare in population. Most common diseases in humans are complex traits, 
like lipid metabolism disorders or hypertension, with no direct correspondence be-
tween a single genotype and the disease phenotype. Often they show diffuse 
phenotypes, high phenocopy rate, genetic heterogeneity, low penetrance, epistasis, 
mitochondrial inheritance and are often influenced by environmental factors (Lander 
and Schork, 1994).  
In Darwin’s theory the fixation of adaptive mutations in a population is an important 
theme on the origin of species by natural selection. In the late 1960s Motoo Kimura 
et al. proposed in his “neutral theory of molecular evolution” that most polymorph-
isms are selectively neutral and are maintained or fixed in population by chance, so-
called genetic drift. In comparison with this background genetic variation signatures 
of positive or negative selection can be identified (Bamshad and Wooding, 2003). 
Other effects due to population demographic history, such as periods of reduced 
population size (bottlenecks), expansions, and subdivided populations are problem-
atic to determine whether a signature is caused by selection. Different approaches 
have shown to be suitable for detecting selection depending on the window of evolu-
tionary time. Figure 5 names briefly the different signatures of selection in an esti-
mated evolutionary time frame, in which it can be used to detect moderately to 
strong selection in humans.  
 
 
Introduction 
 
 
18 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Time scales for signatures of selection. 
Different signatures of selection are listed top down. Brief explanation and 
the common statistical methods for their detection are put in brackets.  
Proportion of functional changes (mutations that alter protein function are 
usually deleterious and are thus less likely to become common or reach 
fixation; McDonald-Kreitman test); Heterozygosity/rare alleles (Reduction 
in genetic diversity, increase of allele also increase variants at nearby ge-
nomic locations leads to low diversity; Tajima’s D, Fu and Li’s D); High-
frequency derived alleles (hitchhiking with favoured new allele creates 
region containing many high-frequency derived alleles; Fay and Wu’s H); 
Populations differences (selection in subpopulations due to different envi-
ronments; Fst test); Length haplotypes (allele rises rapidly enough that 
recombination does not break down the association with nearby alleles 
creating long haplotypes; EHH and iHS) (mya, kya: million years, thousand 
years; adapted from Sabeti et al., 2006). 
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1.9  Association and cohort studies 
Different genetic variants like single nucleotide polymorphisms (SNPs) and 
microsatellites are markers that are widely used to detect association of a gene to a 
phenotype. The usually bi-allelic SNPs are defined to have at least an allele fre-
quency of 1% or more in the population. They occur every 100-300bp and show a 
low heterozygosity. SNPs have the advantage of low mutation rates and little geno-
typing costs for large-scale and high-troughput genotyping (Brookes, 1999; Gray et 
al., 2000; Emahazion et al., 2001; Burgner et al., 2006). The frequency of occur-
rence and genomic location is proportional to the SNP’s influence on the gene: From 
non-coding regions, regulatory hotspots to coding regions with synonymous, non-
synonymous, missense and nonsense effects on translation. More than 11.5 million 
SNPs are found contributing to 90% of the genetic variation in the human genome 
and because of their low mutation rate they serve as reliable markers of molecular 
evolution (Lander et al., 2001, Burgner et al., 2006; Madsen et al., 2007). 
Mainly two kinds of study designs are used to localize the genes underlying human 
disease: genome-wide and candidate gene association studies. An advantage of 
genome-wide association, mostly linkage mapping, studies is that no assumptions 
about potential involved genes have to be made whereas candidate gene studies 
that concentrate on polymorphisms in specific genes have a higher density of tested 
polymorphisms. The problem of low resolution is exemplified in a genome-wide as-
sociation study in West Africa, in which HbS was not associated with malaria until 
the genomic region was re-sequenced (Jallow et al., 2009). 
Candidate gene association studies are better suited for detecting genes underlying 
common and more complex diseases where the risk associated with any given can-
didate gene is relatively small (Risch and Merikangas, 1996; Kwon and Goate, 
2000). Furthermore, in contrast to linkage mapping studies, that require large fami-
lies with disease affected and unaffected individuals, candidate gene approaches 
can be performed with unrelated subjects or small families. A major difficulty lies in 
the identification of potential candidate genes by experimental data. 
Both study types can be realized within cohort or case-control studies. Additional 
types of epidemiological studies include cross-sectional and ecological, or correla-
tion studies providing a weaker informative value compared to cohort and case-
control studies (Schoenbach and Rosamond, 2000). 
A prospective cohort study data is the longitudinal observation of healthy subjects 
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with the characteristic being studied, e.g. disease. Cohort studies are considered as 
gold standard in observational epidemiology (Schoenbach and Rosamond, 2000). 
 
Case-control studies start with the identification of persons with the disease of inter-
est and a suitable control group of subjects without the disease. The purpose of the 
control group is to estimate the baseline frequency of the genetic variant in the 
population. The main advantage of cohort studies is that it allows complete informa-
tion on the subject’s disease, including quality control of data, provides a clear tem-
poral sequence of disease, measurement of potential confounders and give an op-
portunity to study multiple outcomes related to a specific disease. Disadvantages 
include a possible change during the course of the study, high-cost for follow-up 
monitoring and thus a small number of subjects (Szklo, 1998). In contrast, case-
control studies allow studying a large number of subjects at relative low cost. Case-
control studies however are prone to selection bias and are more suitable to study 
rare diseases but lack of validation of information on exposure or other covariates 
and their retrospective character limits the power of conclusions. 
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2 Aim of study 
Despite all international efforts P. falciparum malaria is one of the major health bur-
dens in developing countries. The recent detection of tolerance against artemisinins, 
the key component of all current first-line antimalarial drug combinations (Dondorp 
et al., 2009) underscores the vital need for new affordable drugs and innovative ma-
laria intervention strategies. Critical to present malaria control efforts is the reduction 
of Plasmodium sporozoite transmission from mosquito to man. With the success of 
immunization with RAS and RTS,S/AS01 as the most advanced vaccine candidate 
so far, the sporozoites and liver cell stages are brought into perspective as key 
players. Three genes, apolipoprotein A1 (APOA1), fatty acid binding protein 
(FABP1) and SNAP-associated protein (SNPAPAP), coding for host cell ligands, 
have been identified to interact with parasite proteins (UIS3, UIS4 and UIS7) in a 
yeast two-hybrid screen. However, the roles, if any, of Plasmodium liver stage/host 
interactions on malaria disease outcome remain unknown. Accordingly, identification 
of lipid-binding proteins as host cell ligands for essential proteins at the Plas-
modium/host cell interface permitted a natural genetics approach to validate import-
ant roles for pre-erythrocytic parasite development. 
The aim of this study was to test the hypothesis whether genetic variants encoding 
for proteins that participate in host-parasite liver stage interactions, as exemplified 
by UIS4/APOA1, UIS3/L-FABP and SNAPAP/UIS7, correlate with risk of natural 
infections in a malaria-endemic area. To this end, I genotyped single nucleotide 
polymorphisms (SNPs) in two independent well-characterised groups of children 
from the Kenyan coast (Williams et al., 2005, 2) and analyzed their relationship with 
susceptibility to P. falciparum infections and malaria outcome. Additionally, different 
statistical approaches were used to identify signatures of recent selection within the 
genomic regions of the target genes to explain the evolutionary history of associated 
polymorphisms or genes in the context of host/parasite co-evolution. A further aim 
was to determine the influence of APOA1 on liver cell stage development of in a P. 
berghei model. 
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3  Materials and methods 
3.1  Materials 
 
3.1.1  Equipment 
Analytic Scales: 
Adventurer Pro    Ohaus, Mannheim 
Adventurer Pro (fine scale)   Ohaus, Mannheim 
Autoklave     Systec GmbH, Wettenberg 
Centrifuges: 
J2-MC      Beckman Coulter,  
Megafuge 2.0R     Heraeus Instruments, Hanau 
RC5Bplus           Sorvall  
Fridge      Liebherr, Biberach 
Freezer     Liebherr, Biberach 
Gel electrophoresis system MiniSub-Cell Biorad, Munich 
Genetic Analyzer: 
3130 Genetic Analyzer   Applied Biosystems, Darmstadt  
3130xl Genetic Analyzer   Applied Biosystems, Darmstadt 
Incubator Hera Cell    Heraeus Instruments, Hanau 
Microscopes: 
Confocal Laserscanning Microsc. LSM510 Zeiss, Jena 
Microscope (fluorescence) Axiovert 100M Zeiss, Jena 
Microscope (light) Axiolab    Zeiss, Jena 
Microwave     Intellowave, LG; Willich 
Multiscreen Vacuum Manifold  Millipore, Schwalbach 
Neubauer chamber    Labotec, Göttingen 
Nitrogen tank     CBS, USA 
pH-Meter      Schott 
PCR thermal cycler: 
GeneAmp PCR System 9700  Applied Biosystems, USA 
Mastercycler epgradient S   Eppendorf, Hamburg 
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Pipettes: 
Research 10µl, 20µl 200µl, 1000µl  Eppendorf, Hamburg 
Pipetman Gilson P2, P20, P200, P1000  Abimed, Langenfeld 
Power supply Power Pac 300  Biorad, München 
Spectrophotometer NanoDrop 1000  Peqlab, Erlangen 
Sterile bench Herasafe             Heraeus Instruments, Hanau  
ThermoMixer Compact        Eppendorf, Hamburg 
Vortex Mixer 7-2020         neoLab, Heidelberg  
Water bath Julabo 7A    Julabo 
 
3.1.2 Chemicals 
Agarose     Invitrogen, Karlsruhe 
β-mercaptoethanol    Merck, Darmstadt 
BSA (Bovine Serum Albumin)  Roth, Karlsruhe 
DMEM-Medium (high Glucose)  Pan Biotech, Aidenbach 
Dimethyl sulfoxide (DMSO)   Merck, Darmstadt 
EDTA (Na2EDTA)    Clonetech, Heidelberg 
Ethidium bromide   Sigma Aldrich, Taufkirchen 
Ethanol 100%    Roth, Karlsruhe 
Fetal calf serum (FCS)   Gibco Invitrogen, Karlsruhe 
Formaldehyde    Merck, Darmstadt 
Geneticin (G418)   Gibco Invitrogen, Karlsruhe 
Glycerol    Roth, Karlsruhe 
HBSS (Hanks Balanced Salt Sol.)   Pan Biotech, Aidenbach 
Hi-Di formamide   Applied Biosystems, Darmstadt 
HPLC H2O    Roth, Karlsruhe 
Methanol    Roth, Karlsruhe 
Sodium acetate   Roth, Karlsruhe 
Sodium chloride   Merck, Darmstadt 
Trypan blue    Roth, Karlsruhe 
PBS (tablets)     Gibco Invitrogen, Karlsruhe 
POP7 polymer   Applied Biosystems, Darmstadt 
RPMI 1640-Medium   Gibco Invitrogen Karlsruhe 
(+25mM HEPES, + L-Glutamine) 
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Panserin PX10 (serum-free medium) Pan Biotech, Aidenbach 
Trypsin/EDTA solution  Gibco Invitrogen, Karlsruhe 
 
3.1.3 Consumables 
ABgene PCR plates        Thermo Scientific, Waltham,USA 
chamberslides    LabTek 
cell culture flasks (25cm2, 75cm2)  Renner, Dannstadt-Schauernheim 
cover slides      Marienfeld, Lauda-Königshofen 
cryo-tubes      NALGENE 
culture well plates (24, 6 well)   Greiner Bio-one, Frickenhausen 
Eppendorf tubes (1,5ml)    Eppendorf, Hamburg 
Eppendorf tubes (0,5ml)   Eppendorf, Hamburg 
filter, sterile (Ø 0,2µm)   Schleicher und Schuell, Einbeck 
Filter Tip 10E, 20, 100, 200, 1000     Greiner bio-one, Frickenhausen 
glass slides      Marienfeld, Lauda-Königshofen 
gloves      VZM, Heidelberg 
Parafilm      Pechiney Plastic Packaging 
PCR reaction tubes (0,2ml)    Greiner Bio-one, Frickenhausen 
PCR softstrips 0,2ml, colour        Biozym Scientific, Oldendorf 
pipette tips      Greiner Bio-one, Frickenhausen 
pipette tips w. filter    Greiner Labortechnik, Nütringen 
RNase free Biopure 1,5 ml       Eppendorf, Hamburg 
single use pipettes  (1, 2, 10 ,25ml)   Corning Incorporation, Bodenheim 
syringes      BD Microlance, Becton Dickinson 
syringe needles    BD Microlance, Becton Dickinson 
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3.1.4 Buffers, Media and Solutions 
TE-Buffer (Tris-EDTA):   
10 mM Tris/HCl pH 7.6  
1 mM EDTA 
 
50xTAE Buffer:  
242 g Tris   
57.1 ml Acetic acid   
50 mM EDTA pH 8 
 
PBS (pH 7,4): 
137mM NaCl 
27,mM KCl 
9,2 mM Na2HPO4 
1,5 mM KH2PO4 
 
DMEM complete: 
445ml DMEM-Medium (high-glucose) 
50ml FCS 
5ml Penicillin/Streptomycin (sterile filtered) 
 
Freezing solution: 
20% DMSO, 
80% FCS 
Round-up solution (100x; sterile filtered): 
60mg Penicillin 
100mg Kanamycin 
50mg Fluocytosin 
10mg Chloramphenicol 
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3.1.5  Enzymes, ladder, antibodies, vector 
Taq Polymerase   Fermentas, St. Leon-Rot 
Endonuclease MspI   New England Biolabs, Frankfurt M. 
Shrimp Alkaline Phosphotase  USB, Staufen 
Exosap-it    USB, Staufen 
Exonuclease I    Fermentas, St. Leon-Rot 
Generuler 1kb, 100bb, 50bp     Fermentas, St. Leon-Rot  
α-PbHSP70          AK. Müller, Heidelberg 
α-Mouse Alexa 488      Invitrogen, Karlsruhe 
pcDNA™3.1, 5-His      Invitrogen, Karlsruhe 
 
 
3.1.6 Kits 
5 Prime MasterMix   5 Prime/ VWR, Darmstadt 
BigDye v1.1 Cycle Sequencing Kit Apllied Biosystems, Darmstadt 
GenomiPhi DNA Amplification Kit  GE Healthcare, Freiburg 
HiFect Kit    Lonza, Cologne 
LongRange PCR Kit   Qiagen, Hilden 
Power SYBR Green Master Mix Applied Biosystems, Darmstadt 
QIAamp DNA Blood Mini Kit   Qiagen, Hilden 
RETROscript Kit   Ambion, Darmstadt 
RNeasy Mini Kit    Qiagen, Hilden 
SNaPshot Multiplex System Kit Applied Biosystems, Darmstadt 
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3.1.7 Oligonucleotides 
All primers were purchased from MWG-Biotech (Ebersberg). 
 
Table 2: Primer for APOA1 re-sequencing  
ID sequence length (bp) 
Apo_Promo_for TTTTGGAGGCGGACAATATC 20 
Apo_Promo_rev CCTGTTGCTGCTCACTGGT 19 
Apo_A1_for GGGACAGAGCTGATCCTTGA 20 
Apo_A2_rev CTGAGATCTGAGCCGAAAGG 20 
Apo_B1_for AGAGGCAGCAGGTTTCTCAC 20 
Apo_B2_rev TTCTCCTCTCCGAAGACAGC 20 
Apo_C1_for CTTCTTCACCACCTCCTCTGC 22 
Apo_C2_rev ATCTCCTCCTGCCACTTCTTCT 22 
Apo_D1_for AGAGATGAGCAAGGATCTGGAG 22 
Apo_D2_rev AAGCTGCTTCCCACTTTG 19 
Apo_E1_for GAGCGCTCTCGAGGAGTACA 22 
Apo_E2_rev TCCGCTGTGACTTCCTTTCTAC 22 
 
 
Table 3: Primer for Long Range PCR 
ID sequence 
length 
(bp) 
product 
(kb) ET 
ApoA1long_for AAGTTCCACATTGCCAGG 19 
ApoA1long_rev TGAGCCTTGCTAAGGCAG 19 
2.4 2.5’ 
FABP1long_for GCAGGTCAGTCGTGAAGAGG 20 
FABP1long_rev TGTCACCCAATGTCATGGTC 20 
3.4 3.5’ 
Snapaplong_for AGGGCTCTTGGTCTTTCTGG 20 
Snapaplong_rev AGGGCTCTTGGTCTTTCTGG 20 
5 5’ 
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Table 4 a,b,c Primer for SNaPshot Multiplex assays 
All primer for the SNaPshot Multiplex assays are listed in order to the run length in 
the electrophoresis. The ID column contains the internally used name and the offi-
cial dbSNP identifier in brackets. The characters +/- indicate the direction of the 
primer in relation to the 5’ transcription start point. In the 4th column concentrations 
of each primer in the used primer mixes are listed. The last column names the nu-
cleotide substitution.  
 
Table 4 a: Primer for APOA1 SNaPshot Multiplex assay 
ID sequence length (bp) µM in Mix SNP 
3b-     
(rs5076) 
TTTTTTTTTCCAGCC 
TATCAGGGGTGA 27 0,8 G/A 
4b- 
(rs7116797) 
TTTTTATTTTTTAAAG-
GAGACA-
GAGCTGGGACT 
33 0,8 G/A 
6d   
(rs5072) 
 
TTTTTTTTTATTTTTCTG
CCTGGA-
GATCCCATTCC 
35 0,8 G/A 
5-  
(rs5073) 
 
TTTTTTTTATTTTTTCA 
CAATGTGGCTCTGTGA
TCA 
36 1 C/T 
7b- 
(rs2070665) 
 
TTTTTTTATTTTTTTTT 
TATTTTTTA-
CAGGCCTCTGCCCCCT 
42 0,8 G/A 
1b-  
(rs12718463) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTCGATCTTGGC
CCTAAGACG 
45 0,8 C/T 
8-  
(rs5070) 
 
TTTTTATTTTT 
TATTTTTTTTTATTTTTT
CACGGGGATTTAGGGA
GAA 
48 0,8 G/A 
9b-  
(rs5069) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTC
AGGTACCCAGAGGCCC 
53 0,6 G/A 
10b+  
(rs670) 
 
TTTTTTATTTTTTTTTTTT
TATTTTTTTTT 
TATTTTTTGTGAGCAG 
CAACAGGGCC 
56 1,5 G/A 
2c+  
(rs5081) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTT
TTAACAACTCCGTGCC
CA GAC 
59 0,8 A/T 
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Table 4 b: Primer for FABP1 SNaPshot Multiplex assay 
ID sequence length (bp) µM in Mix SNP 
rs1d+ 
(rs13400963) 
TTTTTTTTTTTTTCCAAA
AAAC-
TAAGCTGGGTACC 
35 1 A/G 
rs2b+ 
(rs7577401) 
TTTTTTTTTTCATGTA-
CAGGAGGATGTGGC 30 0,8 C/T 
rs3+ 
(rs2919871) 
TTTTTTTTTTTACCCA-
CAAAATTTTTGTGAACC
TCA 
36 0,8 T/A 
rs4b+ 
(rs13399861) 
TTTTTTTTTTTTTTTTTG
GTGGTGATAGGGAGA-
GACTT 
38 0,8 C/T 
rs5+ 
(rs2241883) 
TTTTTTTTTTTTTTTTTTT
GAAGGTGA-
CAATAAACTGGTGACA 
43 1 A/G 
rs6- 
(rs1545224) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTGTTGCGCTG
AGCAGAAAGG 
46 0,8 A/G 
rs7+ 
(rs2197076) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTGGTCCTA
CAGGAAACCAGA 
49 1 T/C 
rs8+ 
(rs6711957) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTGAA-
GAATAATA-
CATACCTGGTTGGG 
52 1 T/C 
rs9+ 
(rs28452712) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTT
GGGCTTGTCAGCAG-
CATC 
55 0,6 A/G 
rs10- 
(rs11678114) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTT
GACACAACTAGGCA-
CACAGC 
58 1 C/T 
rs11- 
(rs1123605) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTT
TAGGAAA-
GAAGTTTGGGGGTTG 
60 0,6 A/G 
 
 
 
Table 4 c: Primer for SNAPAP SNaPshot Multiplex assay 
ID sequence length (bp) µM in Mix SNP 
rs1b- 
(rs3806234) 
TTTTTTTTTTGAAAT-
GAGTCTAGCGCGAAC 31 0,8 C/T 
rs3c+ 
(rs35903030) 
TTTTTTTTTTTTTTTTTTT
TTTCGACCTTTTCGCGA
AGG 
40 0,8 G/C 
rs4+ 
(rs16835479) 
TTTTTTTTTTTTTTTTTTT
TTTCTGGAGTTCCTGC
GACC 
39 1 A/C 
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rs5b+ 
(rs16835481) 
TTTTTTTTTTTTTTTTTTT
TGCTTTCCCTCA-
GAACAAGAGAT 
42 0,8 G/A 
rs12+ 
(rs12742195) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTCTCTTGCCTGT
AATCCCAGC 
45 1,5 A/G 
rs6- 
(rs8532) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTCAGGGCCAC
CTTCTGATC 
45 0,8 C/T 
rs7b+ 
(rs6692298) 
TTTTTTTTTTTTTTTTTTT
TTTTTAATTTTAAAATTC
TTTGGGGAAAG 
52 0,8 G/C 
rs8b- 
(rs1802461) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTGCTGT
TTCCTTGGCAACAC 
51 0,8 A/T 
rs9+ 
(rs16835489) 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTGAT-
GAGCCTATGGACTCAG
TAGC 
54 0,8 A/C 
rs13+  
(rs12755522) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTG
AGACCAGCCTGAC-
CAACATA 
57 1,5 G/T 
rs10b+  
(rs41305092) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTCCTA
TGGACTCAGTAGCA-
CAAGTA 
57 1 C/T 
rs11-  
(rs7345) 
 
TTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTT
GTCCTGAAGAAGG-
TAAGCCTCA 
60 0,8 A/C 
 
 
Table 5: Primer for PCR product used in rs670 RFLP assay 
ID sequence length (bp) product (bp) 
ApoA1_MspI_for CCCACTGAACCCTTGACC 18 
ApoA1_MspI_rev CACCTCCTTCTCGCAGTCTC 20 
235 
 
 
Table 6: Primer for Real-Time PCR 
ID sequence length (bp) 
PbMSPI_for AAATAAATCTGGTTTGGTAGGAGAAGG 27 
PbMSPI_rev CCGCAGTTTGACAACCAGCAGTTGG 25 
Pb18s_for AAGCATTAAATAAAGCGAATACATCCTTAC 30 
Pb18_rev GGAGATTGGTTTTGACGTTTATGTG 25 
GAPDH_for CTTCTTGCACCACCAACTGC 20 
GAPDH_rev CGTTCAGTTCAGGGATGACC 20 
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ApoMouse_for GGAAAACTGGGACACTCTGG 20 
ApoMouse_rev CGGTAGAGCTCCACATCCTC 20 
ApoHomo_for ACCTGGAAAAGGAGACAGAGG 21 
ApoHomo_rev AGTGGGCTCAGCTTCTCTTG 20 
ApoRatus_for CACTGTGTACGTGGATGTGC 20 
ApoRatus_rev CGCATCTGATCGCTGTAGAG 20 
 
 
3.1.8 The Mild and Severe Malaria cohorts 
 
3.1.8.1 Mild Malaria Cohort dynamic follow-up study 
The Mild Malaria cohort was designed as a dynamic cohort with entries and exits of 
subjects during the time of follow-up. Details in design of the mild-disease cohort 
study have been described in detail previously (Williams et al., 2005, 2). In brief, 
participants living within the area of Ngerenya and Chonyi of Kilifi District on the 
Kenyan Coast were monitored for clinical events from September 1998 to August 
2001 by weekly active surveillance. Additionally, intercurrent clinical events were 
tracked through a dedicated outpatient clinic. Children born into study households 
were recruited at birth. Participants exited the study if informed consent was with-
drawn, if they died or if they moved away for more than 2 months. In addition, 4 
cross-sectional surveys to evaluate the prevalence of P. falciparum parasites were 
conducted to assess the prevalence of falciparum parasites during the study inter-
val. The data include anthropometric data like age, sex, ethnic, genotypes of sickle 
cell and α-thalassaemia. Malariometric consists of species and parasite density cal-
culated by number of P. falciparum parasites per microlitre of blood. It was calcu-
lated by reference to the number of parasites / 200 white blood cells or 500 red 
blood cells.  If a blood count was available the parasitaemia was calculated by re-
ference to the actual blood count.  If no blood count was available the parasitaemia 
was calculated assuming a white blood cells of 8x109/L or a red blood cells count of 
5x1012/ L. Accessory data about seasons and if the patient was absent at the regular 
monitoring were included. 
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3.1.8.2 Severe Malaria cohort study 
The Severe Malaria cohort was designed to record children with severe malaria 
(cases) and children without known severe events (controls). The design and ac-
complishment has been described in detail in Snow et al. (2000) and Williams et al. 
(2005, 2). Briefly, between May 1992 and April 1995 children born within a defined 
rural study area to the north of the Kilifi research unit were recruited into a fixed birth 
cohort. The study area was the same but larger part of the same geographic area in 
which the Mild Malaria Cohort study was conducted. Admissions to the paediatric 
wards at Kilifi District Hospital (the closest hospital facility to the study area) from 
participants of this cohort until December 1997 were recorded. Between May and 
October 2000 2,695 resident surviving members of this cohort were invited to pro-
vide a blood sample. In 2,104 children typing for both HbS and α-thalassaemia was 
completed.  
 
 
3.1.9 Databases 
Case Western Reserve University (CWRU) Genomics 
http://cmbi.bjmu.edu.cn/genome/candidates/SNPs.html 
 
dbSNP 
http://www.ncbi.nlm.nih.gov/projects/SNP/ 
 
Ensembl Genome Browser 
http://www.ensembl.org/index.html 
 
Haplotter 
http://hg-wen.uchicago.edu/selection/haplotter.htm  
 
International HapMap Project 
http://www.hapmap.org/ 
 
PharmGKB (The Pharmacogenomics Knowledge Base) 
http://www.pharmgkb.org/ 
 
UCSC Genome Bioinformatics 
http://genome.ucsc.edu/ 
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3.1.10 Software 
AutoDimer v. 1.0         http://www.cstl.nist.gov/strbase/AutoDimerHomepage- 
 /AutoDimerProgramHomepage.htm 
BioEdit v 7.0.9  http://www.mbio.ncsu.edu/BioEdit/bioedit.html 
DNA Sequencing-   Applied Biosystems, Darmstadt 
Analysis v. 5.2. 
Genemapper v. 4.0  Applied Biosystems, Darmstadt 
gPLINK v. 1.04  http://pngu.mgh.harvard.edu/~purcell/plink/gplink.shtml 
Haplotter   http://hg-wen.uchicago.edu/selection/haplotter.htm 
Haploview v. 3.32  http://www.broadinstitute.org/mpg/haploview 
ImageJ v. 1.42q  http://rsbweb.nih.gov/ij/ 
Microsoft Office 2008  Microsoft Corporation, Santa Rosa, USA 
PGA package   http://dceg.cancer.gov/bb/tools/pga 
PHASE v. 2.1   http://www.stat.washington.edu/stephens/phase.html 
Primer3   http://frodo.wi.mit.edu/primer3/ 
Prism v. 5.0b   GraphPad Software Inc., La Jolla, USA 
SBEprimer v.1.1β   http://www.zaik.uni-  
koeln.de/AFS/Projects/Bioinformatics/sbeprimer.html 
STATA MP 10.1   Stata Corporation, College Station, USA 
Sweep v. 1.0   http://www.broadinstitute.org/mpg/sweep/ 
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3.2 Methods 
 
3.2.1 Molecular biology 
 
3.2.1.1  Isolation and purification of nucleic acids 
3.2.1.1.1 Isolation of genomic DNA 
Genomic DNA (gDNA) isolation from blood and hepatocyte culture was conducted 
with a silica-membrane-based DNA purification method from QIAamp DNA Blood 
Mini Kit (Qiagen). Cells containing DNA were lysed and the DNA was stabilized by a 
combination of buffers. After adding ethanol the solution was loaded on a column 
where the DNA was bound to the silica membrane. The bound DNA was eluted in 
H2O after washing with different buffers to remove debris and salts. The manufac-
ture’s protocol was followed for all steps. 
 
 
3.2.1.1.2  Isolation of RNA 
Isolation of RNA was performed with a silica-membrane based method using 
Qiagen’s RNeasy Mini Kit. The protocol provided by the manufacturer was followed.  
 
 
3.2.1.2  Purification of nucleic acids 
 
3.2.1.2.1  Ethanol precipitation 
DNA is solved in water due to its polarity. Adding a salt to this solution the charge of 
the DNA is neutralized and it precipitates. This reaction is facilitated by ethanol and 
temperature. Centrifugation allows removing the supernatant. A subsequent wash-
ing step with 70% ethanol removes the salt from the DNA. Re-suspending in TE-
Buffer allows long-time storage of solved DNA. 
 
 
3.2.1.2.2  Purification of GenomiPhi samples 
For better a performance of downstream applications all GenomiPhi samples 
(3.2.1.4.3) were purified using ethanol precipitation. To each sample 20µl dH2O and 
4µl of a pre-mixed sodium acetate (1.5M)/ EDTA (250mM) buffer was added. After 
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mixing, 100µl chilled ethanol (100%) was added and this mix was stored overnight 
at -20°C. Next day it was centrifuged at 12,000rpm for 20 minutes at 4°C. The 
supernatant was discarded and 150µl of chilled 70% ethanol was added. Again, it 
was centrifuged at 12,000rpm for 10 minutes and the supernatant was discarded. 
The pellet was dried at RT for 10 minutes, re-suspended in 40µl of TE buffer and 
stored at 4°C. 
 
 
3.2.1.2.3  Purification of sequencing products 
Best purification of sequencing products (3.2.1.7) was achieved with a different pro-
tocol for ethanol precipitation: 
80µl of HPLC H20 and 10µl sodium acetate (3M) were added to the complete se-
quencing reaction. After adding 250µl of ethanol (100%) the mix incubated 20 min-
utes at RT followed by a centrifugation step of 20 minutes at 13,000rpm at RT.  
The supernatant was discarded and the pellet was washed with 250µl of 70% etha-
nol. Again the mix was centrifuged at 13,000rpm for 10 minutes and the supernatant 
removed. The pellet was dried at 37°C for 5 minutes and re-suspended in 20µl Hi-Di 
formamide to prevent formation of secondary structures. 
 
 
3.2.1.2.4 Purification of PCR products 
All PCR products used for sequencing were purified with the vacuum filtration appli-
cation MultiScreenHTS Vacuum Manifold (Millipore). In the single sealed MultiScreen 
PCR 96 Filter Plates primer and other low molecular weight material were washed 
away whereas nucleic acids were hold back if vacuum was applied. Nucleic acids 
were resolved in H2O and retrieved by aspiration. PCR products were diluted in 
100µl dH20 respectively and loaded into the plate. Empty wells were sealed with 
plate sealing tape. Filtration time was around 13 minutes until no liquid in the well 
was left. 50µl of H2O were added to each well and PCR products were re-
suspended. All taken steps were done in accordance to the manufacturer’s protocol.  
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3.2.1.3  Determination of DNA/ RNA concentration 
All DNA and RNA concentrations were determined by photometry. Nucletotides ab-
sorb light at a maximum of 260nm whereas proteins have maximum absorption at 
280nm.  
1 µl of sample containing DNA or RNA was loaded on the spectrophotometer 
NanoDrop 1000 (Thermo Scientific). The manufacturer’s recommended default set-
tings were used for absorption measurement and calculation of the nucleic acid 
concentration. 
 
 
3.2.1.4 Amplification of nucleic acids 
 
3.2.1.4.1 Cleaving of gDNA 
To clear DNA contamination in RNA prior to cDNA synthesis the samples were in-
cubated with DNase I. This enzyme cleaves double stranded DNA in 5' phosphory-
lated oligodeoxynucleotides. For a better performance the TURBO DNase (Ambion) 
was used with the provided protocol of the manufacturer but with an increased incu-
bation time of 45 minutes at 37°C. 
 
 
3.2.1.4.2  Transcription of RNA to cDNA 
The enzyme Reverse Transcriptase is used to transcribe RNA to its complementary 
cDNA as template for downstream real-time PCR. Here, the RETROscript First 
Strand Synthesis Kit (Ambion) was used. First the RNA was heat denaturated to 
clear secondary structures, then cDNA was amplified by the reverse transcriptase 
using the RNA as matrices and at last the enzyme was heat inactivated. 
For transcription of total RNA 1µl oligo dT and 1µl random decamer primer were 
used in the reaction. In all steps manufacturer’s protocol was followed.  
 
 
3.2.1.4.3  Whole Genome Amplification 
Whole genome amplification (WGA) amplifies the whole genome of a sample and 
thus increases the amount of available DNA for further experiments. The proofread-
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ing Phi29 DNA polymerase amplifies nucleic acids strands via a strand displace-
ment reaction.  
 
The whole gDNA of all samples from the Mild Malaria Cohort were amplified with the 
GenomiPhi DNA Amplification Kit (GE Healthcare).  
Therefore, for each sample 1µl of gDNA was mixed with 9µl of provided sample buf-
fer containing random-sequenced hexamer primer. These primer align randomly 
thus allowing random amplification. The mix was denatured at 95°C for 3 minutes 
and immediately cooled down to 4°C on ice allowing the primer to bind. Pre-mixed 
solution of 9µl reaction buffer and 1µl of Phi29 polymerase was added to the cold 
sample and incubated for 2 hours at 30° C. In this time dNTPs in the reaction were 
converted into high-molecular-weight fragment copies of the template DNA by the 
polymerase. The latter was inactivated by a post-amplification heat inactivation step 
at 65°C for 10 minutes. All GenomiPhi products were stored at 4°C until purification 
(3.2.1.2.2). 
 
 
3.2.1.4.4  Polymerase Chain Reaction  
Polymerase chain reaction (PCR) was used to amplify DNA fragments in vitro. For 
selection of the desired segments two primer have been used complementary to the 
template DNA. The reaction takes place in 3 steps: 
At the first step the hydrogen bonds between the DNA strands are released at 94°C. 
Then the reaction is cooled down to the temperature between 50-61°C at which the 
primer anneal.  At the last step, so called elongation step, the 3’ end of the primer 
were elongated with dNTPs by the polymerase. All 3 steps were repeated in cycles 
that allow copying the fragment million times. 
 
 
3.2.1.4.4.1  PCR for APOA1 re-sequencing 
For the re-sequencing of APOA1 6 sets of overlapping DNA fragments were ampli-
fied with PCR from 50 random individuals from Kilifi at the East Coast of Kenya. The 
total product size was ∼2,4kb. Polymerase and ingredients from Fermentas were 
used according to the manufacturer’s protocol. For all PCR a single reaction without 
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DNA was used as a negative control. Additionally, a positive control of known per-
formance was used in all established PCR. 
All sequences were re-assembled in the BioEdit v. 7.0.9 software (3.2.3.2). 
 
The Master Mix for each reaction of 50µl was prepared as follows: 
H2O   36,5µl 
10x PCR-Buffer   5µl 
MgCl2      3µl 
dNTPs       2µl 
5’ primer    1µl 
3’ primer    1µl 
Taq     0.5µl 
DNA     1µl 
 
The reaction was run on a Mastercycler epgradient S (Eppendorf) cycler with follow-
ing programme: 
 
95°C  3min 
95°C  30sec 
57°C  50sec 
72°C  1min 
72°C  10min 
  4°C  hold 
 
 
 
3.2.1.4.4.2  Long Range PCR for SNaPshot assay 
The Long Range PCR Kit (Qiagen) was used for amplifying the whole gene of 
APOA1, FABP1 and SNAPAP in the subset of the Mild Malaria Cohort. The ampli-
fied products included all target SNPs of each gene. They were used as a template 
for the SNaPshot assays (3.2.1.8).  
 
 
33 cycles 
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The protocol provided by the manufacturer was followed. A final volume of 25µl per 
reaction was composed of: 
 
H2O             19.85µl 
LongRange-Buffer             2.5µl 
dNTP-Mix              1.25µl 
5’ primer              0.2µl 
3’ primer              0.2µl 
LongRange-polymerase 0.2µl 
DNA               0.8µl 
 
The PCR was performed on ABI 9700 Thermal Cycler: 
 
93°C  3min 
93°C  15sec 
AT  30sec 
68°C  ET (see table 3) 
4°C  hold 
 
3.2.1.4.4.3  PCR for rs670 RFLP assay 
PCR with the 5-Prime-MasterMix (5-Prime) was used to amplify the template for the 
SNP rs670 RFLP assay (3.2.1.6).  
 
A single reaction with a Volume of 20µl consisted of: 
H2O    10µl 
5 Prime MasterMix    8µl 
5’ primer    0.6µl 
3’ primer    0.6µl 
DNA     0.8µl 
 
The reaction was performed on an ABI 9700 Thermal Cycler with the cycle protocol 
from the PCR for APOA1 re-sequencing (3.2.1.4.4.1). 
 
38 cycles 
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3.2.1.5   Gel electrophoresis 
Gel electrophoresis was used to visualize DNA fragments from PCR or RFLP as-
says. In an electric field the negatively charged DNA is forced to the anode. The 
DNA fragments were embedded in a matrix of agarose polymers. Separation is 
achieved due to movement of DNA fragments in this matrix proportional to their size.  
The agarose powder was dissolved in 1xTAE-Buffer by heating and 1µg/ml ethidium 
bromide was added. For fragments smaller than 500bp a 2% and for bigger sizes a 
1% agarose concentration was used. The DNA samples were mixed with 0.3 vol-
umes of Loading Dye (Fermentas) and loaded into the gel pockets. 8µl of 1kb or a 
50bp Marker (Fermentas) was used for sizing and the gel was run at 5V/cm in a gel 
chamber (Biorad).  
The intercalated ethidium bromide in the DNA was excited using UV-light and 
photographed with the Gel Doc XR or Chemi Doc XRS (Biorad). 
 
 
3.2.1.6  MspI Restriction Fragment Length Polymorphism Assay 
A Restriction Fragment Length Polymorphism assay (RFLP) was used to genotype 
samples from the Severe Malaria Cohort for the SNP rs670. Endonucleases are 
widely used to cleave phosphodiester bonds in DNA strands. Here, the endonu-
clease MspI (New England Biolabs) was used that recognize and cleaves (^) a se-
quence consisting of      5’-CCG^G-3’.  
A PCR product of 235bp was amplified in a PCR with 5-Prime-Mastermix 
(3.2.1.4.4.3). 5µl of this product was digested overnight with 3U of MspI in 4µl H2O 
and 1µl NEBuffer 4 (10x) at 37°C. 
Next day the fragments were separated in 2.5% agarose gels by electrophoresis 
and visualized with the GelDoc XR or ChemiDoc XRS. The PCR product was only 
cleaved when the G genotype (reverse strand: C) was present. 
For all master mixes a negative control and a positive control for all the three geno-
types (AA, GA or GG) were performed. 
 
 
3.2.1.7  Sequencing of PCR products 
Here, the chain terminator sequencing method developed by Sanger et al. (1977) 
was used. Comparable to PCR the amplification is performed with primer, a poly-
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merase and dNTPs. Latter contain a low concentration of labelled chain terminating 
dideoxyribonucleotide triphosphate (ddNTPs). Integration of these leads to an ampli-
fication termination that result finally in a mixture of DNA fragments with varying 
length that are terminated only at positions where ddNTP are integrated. The frag-
ments are then size-separated by electrophoresis and the sequence is determined 
by the run length and different labelled ddNTPs, which fluoresces at a different 
wavelength. Contrary to PCR the sequencing reaction is not exponential. 
 
All sequencing was performed by GATC (Konstanz) or with the 3130 Genetic Ana-
lyzer (ABI) in combination with the Big Dye Terminator Mix v1.1 Kit (ABI). For latter 
the purified PCR product (3.2.1.2.4) was added to a master mix with a total volume 
of 10µl: The final master mix was composed of:  
 
HPLC H2O     4.5µl 
Big Dye Sequencing Buffer (5x)  1.5µl 
Primer  (5nM)     1µl 
Big Dye Terminator Mix v1.1   1µl 
PCR product     2µl 
 
The PCR was set up in a Mastercycler epgradient S (Eppendorf): 
 
96°C  1min 
96°C  10sec 
58  5sec 
60°C  4min 
4°C  hold 
 
After completion the product was purified using ethanol precipitation (3.2.1.2.3) and 
the pellet was re-suspended in 20µl Hi-Di formamide. Then all reactions are loaded 
into the 3130 Genetic Analyzer. The manufacturer’s default settings for Big Dye v1.1 
in combination with a 36cm capillary and POP7 polymer were used for electropho-
resis. The results were analyzed with ABI DNA Sequencing Analysis Software v. 
5.2. 
 
 25 cycles 
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3.2.1.8  Primer extension assay with SNaPshot Multiplex Kit 
In a primer extension assay with the SNaPshot Multiplex Kit (ABI) a primer binds to 
the template and only a single nucleotide complementary to the matrix is incorpo-
rated at 3’ end of the primer (Figure 6). Contrary to PCR or sequencing the single 
incorporation is caused by exclusive presence of fluorescent labelled ddNTPs in the 
SNaPshot Multiplex reaction. This method was approved to be accurate, cost-
effective and suitable for large amounts of clinical data (Pati et al., 2003; Ben-Avi et 
al., 2004). 
The primer with labelled nucleotide is separated by electrophoresis. Multiplexing is 
achieved by varying primer length. 
  
 
 
 
Figure 6: Primer extension with SNaPshot Multiplex Kit 
SNP primer anneals 5’ of SNP and is extended by a single base unit. Multiplexing is 
achieved by using ascending lengths of poly-T tails, which results in different electrophoretic 
mobilities thus all primer in the reaction can be separated by their size. 
 
 
In the SNapShot Multiplex assay the product from the Long Range PCR 
(3.2.1.4.4.2) was used as the template for each gene. The single reaction contained 
10 primer for APOA1, 12 for FABP1 and 12 for SNAPAP. Differentiation between 
the primer was possible due to a varying length of a poly-T tail at 5’ of the primer. 
Separation of the SNaPshot products was achieved by electrophoresis on a 3130 or 
3130xl Genetic Analyzer. Final Analysis was conducted with the Genemapper soft-
ware v. 4.0 (ABI). 
 
For the SNaPshot Multiplex reaction 5µl of the template were digested with 2µl of a 
pre-mixed solution containing 3U Exonuclease 1 and 2U Shrimp Alkaline 
Phospotase (SAP) to degrade primer and dNTPs from prior PCR. The Exonuclease 
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1 digests single stranded DNA whereas SAP catalyses the release of 5'- and 3'-
phosphate groups resulting in un-incorporatable dNTPs/ ddNTPs. 
The mix was incubated at 37°C for 65 minutes and enzyme was heat inactivated at 
75°C for 15 minutes. After cooling down to 4°C 3µl were transferred to a pre-cooled 
mix that consisted of 2.5µl SNaPshot Multiplex Ready Reaction Mix, 1µl of the spe-
cific primer-mix and 3.5µl HPLC H2O.  
Subsequent thermal cycling was perfomed on ABI Thermal Cycler 9700 or Eppen-
dorf Fast Cycler:  
 
96°C  1min 
96°C  10sec 
50  5sec 
60°C  30sec 
4°C  hold 
 
 
To avoid co-migration of unincorporated ddNTPs along with the primer fragments 
the whole reaction mix was digested with 2U SAP for 60 minutes at 37°C with adja-
cent enzyme heat inactivation at 65°C for 15 minutes. 
 
0.8µl of the digested SNaPshot product was mixed with 8.9µl of Hi-Di formamide 
and 0.3µl LIZ 120 size standard (ABI) and loaded into the 3130 or 3130xl Genetic 
Analyzer. In all master mixes a negative control without template DNA was per-
formed to test for contamination. 
The electrophoresis was run with a 36cm capillary and POP7 polymer on the Ge-
netic Analyzer. The manufacturer’s recommended program set up was used. Only 
the run time was reduced to 600 seconds to speed up the assay. 
 
 
 
 
 
 
 
 25 cycles 
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3.2.2  Cell culture 
 
3.2.2.1  Hepatoma cell culture 
The human hepatoma cell line Huh7 (provided by AK. Müller) and the murine hepa-
toma cell line Hepa1.6 (provided by G. Montagna) were cultured in vitro. They were 
kept in cell culture flasks in 15ml DMEM complete medium in an incubator with 37ºC 
and 5% CO2. 
For a stable growth the adherent cells were splitted when the flask bottom was con-
fluently overgrown. Therefore, medium was removed and the cells were washed 
with HBSS medium to remove serum remnants. For detaching the hepatocytes were 
incubated with 3ml Trypsin/EDTA solution for 3 minutes at 37ºC. Then the re-
suspended cells were centrifuged at 2000rpm for 3 minutes and the supernatant 
was removed. The cell pellet was washed in 6ml HBSS, centrifuged and the super-
natant was again discarded. The pellet was re-suspended in 3ml DMEM complete. 
A 1ml aliquot was transferred into a new flask. All media were pre-warmed to 37ºC 
using a water bath. 
 
 
3.2.2.2  Determination of cell concentration 
Counting the hepatocytes was necessary for plating a specific cell number in wells 
for the experiments. Washed and re-suspended hepatocytes (3.2.2.1) were stained 
with Trypan blue in a 1:10 dilution. This vital staining allows counting of living cells 
because cells with a functional membrane remain uncoloured in the blue back-
ground. The living cells were counted in a chamber with Neubauer rulings. The con-
centration of cells were calculated by:  
 
 
€ 
cells
ml =
counted cells in 4 squares
4
 
 
 
 
 
 * dilution factor *104  
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3.2.2.3  Freezing and thawing of hepatocytes 
An aliquot of hepatocytes (3.2.2.1) were centrifuged for 3 minutes at 2000rpm and 
the pellet was re-suspended in the freezing solution. Immediately the suspension 
was frozen at -80ºC. Later the frozen cells were stored in liquid nitrogen. 
For thawing the frozen aliquot was thawed quickly in a water bath at 37ºC and 
added to pre-warmed 6ml of DMEM complete. After centrifugation at 2000rpm for 3 
minutes and supernatant removal the pellet was re-suspended in 3ml DMEM com-
plete and then added to a cell culture flask with 10ml DMEM complete. The flask 
was stored in the incubator at 37ºC. 
 
 
3.2.2.4  Transfection of hepatocytes 
For an APOA1 overexpression model the hepatoma cell line Huh7 was transfected. 
The Huh7 cell line was provided by AK. Müller (Heidelberg) and the pcDNA3.1/V5-
His A vector was provided by G. Montagna (Max PIanck Institute, Berlin). The used 
vector expressed ApoA1 cDNA of R. norvegicus. ApoA1 expression was controlled 
by the Cytomegalovirus-Promotor (CMV). The HiFect Kit (Lonza) was used for 
transfection of the vector into the cell lines. 24 hours before transfection 100,000 
hepatocytes per well were plated in 500µl DMEM complete in a 24well plate. The 
transfection was done according to the manufacturer’s protocol for 24well plates. 
Five hours after transfection the medium was replaced with DMEM complete and 
another 24 hours later the medium was changed again including 800µg/ml Geneticin 
G-418 (Gibco Invitrogen) as a selection marker. Geneticin G-418 blocks the poly-
peptide synthesis in eukaryotic and prokaryotic cells by inhibition of the elongation 
step. The vector contains the neo gene from Tn5 encoding an aminoglycoside 3‘-
phosphotransferase that results in resistance to G-418. 
A mock-transfected Huh7 was created the same way but with a different vector that 
was not expressing ApoA1. The transfected Hepa1.6 cell line was provided by G. 
Montagna. Successful translation of ApoA1 was verified by Western blot (Montagna 
G, personal communication).  
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3.2.2.5  APOA1 overexpression assay  
 
 
3.2.2.5.1  Isolation of P. berghei sporozoites 
Anopheles stephensi infected with P. berghei were provided by AK Müller. For isola-
tion of P. berghei sporozoites the salivary glands from mosquitos were isolated 17 
days after the infection with P.berghei. Therefore, the salivary glands were dissected 
out of dazed mosquitos by tweezers, stored in 200µl RPMI 1640 medium with 3% 
BSA on ice and homogenized with a pestle. The homogenate was centrifuged for 3 
minutes at 1000rpm and the supernatant was transferred to a new Eppendorf tube. 
The pellet was re-suspended in 200µl RPMI 1640/ 3% BSA medium and centrifuged 
again at 1000rpm for 3 minutes. Both supernatants were merged and the sporozoite 
concentration in a 1:10 dilution was determined in count chamber with Neubauer 
rulings (3.2.2.2). 
 
 
3.2.2.5.2  Infection of hepatocytes with P. berghei sporozoites 
Hepatocytes were plated 24h prior to infection with P. berghei. For later RNA isola-
tion 100,000 cells per well were plated into 24well plates whereas 30,000 cells per 
well were plated into Labtek slides. Only Panserin PX10 (Pan-Biotech) serum-free 
medium was used. 
The medium was removed before the sporozoites infection. In 24well plates 50,000 
sporozoites per well and in the Labtek slides 10,000 sporozoites per well were 
added in 100µl and 50µl Panserin PX10 medium, respectively. An incubation time of 
90 minutes at 37ºC allowed the sporozoites to invade the hepatocytes. Then the 
medium was replaced with Panserin PX10 containing round up solution (1:1000) to 
prevent contaminations. Every 24 hours the medium was renewed. 
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3.2.2.6  APOA1 overexpression assay analysis 
 
3.2.2.6.1  Isolation of RNA for real-time PCR 
At 24, 48 and 65 hours post infection (pi) the hepatocytes were harvested out of the 
24well plates for RNA isolation (3.2.1.1.2). The cells were washed with HBSS me-
dium and then incubated in Trypsin/ EDTA solution for 3 minutes at 37ºC. The cells 
were added to 1ml DMEM complete, centrifuged at 2000rpm for 3 minutes. DMEM 
was removed and every pellet was re-suspended in 350µl RLT Buffer (Qiagen) con-
taining 10µl/ml β-mercaptoethanol. They were stored at -80ºC. 
 
 
3.2.2.6.2  Quantification of cDNA using Real-Time PCR 
Real-Time PCR enables detection and quantitative measurement of the amount of 
specific DNA molecules in a sample. Based on the principle of PCR, additionally the 
amount of dsDNA is detected after every amplification cycle. For detection of the 
amplified product SYBR Green was used. It forms a complex with dsDNA that emits 
green light if excited with light at 494 nm. The cycle was employed for quantification 
when the fluorescence exceeded the threshold ct. Gapdh (H.apiens or M.musculus) 
was measured for normalization and relative quantification to APOA1 
(R.norvegicus), APOA1 (H.sapiens), 18s (P.berghei) and msp1 (P.berghei). The 
Master mix with H2O and the original RNA was used as negative controls. All reac-
tions and controls were tested in triplicates. The primer were tested for non-specific 
amplifications and primer dimer. Therefore, a single dissociation cycle was run sub-
sequently to a completed real-time PCR. The dissociation curve showed the melting 
point of the amplified product. Primer with a dissociation curve showing more than 
one peak were excluded from the assay. 
Quantification of targeted cDNA copies from the APOA1 overexpression experiment 
was performed on the 7500 Real-Time System (ABI) with Power SYBR Green PCR 
Master Mix (ABI). Fluorescence detection was set at the 60°C step.  
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A single reaction mix of 25µl was composed of: 
H2O   10µl 
Power SYBR Mix 12µl 
5’primer (5nM)  1µl 
3’primer (5nM)  1µl 
cDNA    1µl 
 
 
Programme for real-time PCR: 
95°C  3min 
95°C  10sec 
55°C  15sec 
60°C  45sec 
Dissociation step: 
95°C  15sec 
60°C   1min 
95°C  15sec 
 
Each reaction was performed in triplicates and the mean ct value was calculated. 
The delta ct (Δct) and the delta delta ct (ΔΔct) were calculated by: 
Δct=18s-GAPDH and ΔΔct=Δ ApoTrans – Δ WT 
 
 
3.2.2.6.3  IFA staining and microscopy 
The Indirect Fluorescent Antibody (IFA) staining was used to detect liver cells 
stages. In this method an antibody (AB) interacts with a specific antigen and is label-
led with a second fluorescent AB.  
The medium in Labtek slides was removed at 24, 48 and 65 hours pi. The cells were 
fixed with -20ºC cold methanol for 10 minutes at RT and carefully washed twice with 
FCS/PBS (1:100). Then they were blocked with FCS/PBS (1:10) and stored at 4ºC 
overnight. For staining of liver cell stages the monoclonal anti-P. berghei HSP70 
antibody (α-PbHSP70) from M. musculus was added in a dilution of 1:300 in 
FCS/PBS (1:10). 
40 cycles 
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After an incubation time of 45 minutes at 37ºC the slides were washed 3 times with 
FCS/PBS (1:100). Then the anti-mouse AB (α-mouse-IgG-Alexa 488) in a 1:300 
dilution in FCS/PBS (1:10) was added. Again the slides were incubated at 37ºC for 
45 minutes and subsequently washed 3 times with FCS/PBS (1:100). The nuclei of 
the hepatocytes and parasites were stained with Hoechst (1:1000) for 15 minutes at 
RT in FCS/PBS (1:10). Again the slides were washed 3 times with FCS/PBS 
(1:100). The slides were mounted with glycerol/PBS (1:10) and cover slips. The lat-
ter were sealed with nail polish. 
Liver cell stages were counted under the microscope Axiovert 100M with a 40x 
magnification. For measurement of liver cell stage sizes they were photographed in 
the Confocal Laserscanning Mikroscope LSM 510 using the 63x objective. 25 liver 
cell stages per well and time point were photographed and their area was deter-
mined in ImageJ v. 1.42q (National Institute of Health). The means of liver stage 
area size were compared for significance with a non-parametric unpaired two-tailed 
Student’s t-test. All graphs and calculations were done in Prism v. 5.0b (GraphPad 
Software Inc.). 
 
 
 
3.2.3  Bioinformatical methods 
 
3.2.3.1  Database screening 
Different databases were used to examine and download information about DNA 
sequences, genomic regions, genes and SNPs. DNA sequences were obtained 
from the ENSEMBL Genome Browser and NCBI databases.  
SNP information was gathered at the NCBI dbSNP database and completed with 
information from the CWRU Genomics, PharmGKB, UCSC Genome Browser and 
the HapMap (The International HapMap Consortium, 2007) databases. 
 
 
3.2.3.2  DNA sequence analysis and manipulation 
DNA sequences downloaded from databases or from sequencing were analysed 
with the BioEdit v. 7.0.9 software (Hall et al., 1999). All re-sequenced fragments 
from APOA1 (3.2.1.4.4.1) were reassembled and aligned in BioEdit using APOA1 
Materials & Methods 
 
 
50 
DNA sequences from NCBI (NM_000039) and Ensembl (ENSG00000118137) as 
matrices. 
 
 
3.2.3.3  Calculation of tag SNPs 
For minimizing the number of SNPs in the SNaPshot Multiplex assays and thus re-
ducing genotyping costs, SNPs in the HapMap database were tagged. Tag SNPs 
are a subset of all SNPs in a genomic region. Based on LD they are able to capture 
most information of all SNPs in the genomic region where one SNP allele is unique 
to a particular haplotype (Johnson et al., 2001). De Bakker et al. (2006) verified the 
usage of HapMap DNA samples for selecting tag SNPs in many different ethnics 
around the world. 
 
Tag SNPs in the HapMap Yoruba population (YRI) and in U.S. residents with north-
ern and western European ancestry collected (CEU) by the Centre d'Etude du 
Polymorphisme Humain (CEPH) data were calculated using the implemented Tag-
ger tool (de Bakker et al., 2005). Within each gene they were calculated with an 
r2≥0.8 and a minor allele frequency (MAF) cut-off of 0.05. Only tag SNPs were cho-
sen that showed comparable tagging in the CEU and YRI dataset.  
 
 
3.2.3.4  Primer Design 
 
3.2.3.4.1  Primer Design for PCR and real-time PCR 
Except for the SNaPshot Multiplex assay, all primer were designed using the 
Primer3 web-tool (Rozen et al., 2000). For designing the DNA sequences of tar-
geted genome regions were copied from ENSEMBL or NCBI databases into the 
online accessible Primer3 interface.  
 
 
3.2.3.4.2  Primer Design for SNaPshot Multiplex assay 
Primer for the SNapShot Multiplex assays were designed with the SBEprimer v.1.1β 
software (Kaderali et al., 2003). For every target gene all SNPs flanked by 20bp in 5’ 
and 3’ directions were imported into the programme. The default settings were used 
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and with the “slow check” option possible forward and reverse primer were calcu-
lated. Out of all these primer appropriate combinations were chosen. Hence 
SBEprimer is used for multiplex assay with attached primer all chosen combinations 
were revised for possible formations of primer-dimer and hairpins with the Autodimer 
v.1 software (Vallone et al., 2004) in its default set up.  
A passed primer was first tested solely in a SNaPshot Multiplex reaction for correct 
priming in a sequenced control template. Then all primer for each target gene com-
bined in one mix were tested for primer interactions and artefacts. 
 
The Genemapper v. 4.0 software (ABI) was used to analyze data from the SNaP-
shot Multiplex assays. The assay data were imported directly into the software and 
manufacturer’s settings for analyses were applied. For the automatic allele calling I 
created a panel for each primer combination of the target genes. Therefore, every 
primer was tested solely and a bin for every allele was generated. All these bins 
(two bins per primer) were implemented in the panel for each of the target genes. A 
bin identifies the run length and the fluorescence of the single incorporated labelled 
ddNTP in the electropherogram from each run. 
Genemapper v. 4.0 with applied panels detected and listed the specific alleles for 
every primer automatically. All lists, containing the detected alleles, were exported to 
the software Excel 2008 (Microsoft Corporation).  
All electropherograms were inspected two times manually to account for possible 
electrophoretic shifts due to age and condition of the POP7 polymer and capillaries. 
 
 
3.2.3.5  Genotype data validation 
Genotype data were transformed into the PED-file format. Hence, I used data from 
unrelated individuals thus the mother’s and father’s identifiers were set to “0” and 
the individual ID to “1”. The individual sample name was defined in the pedigree 
name column. Details are available at the gPlink v 1.04 manual. 
For summary statistics and data file validation the genotype PED files were imported 
into the gPLINK v. 1.04 software (Purcell et al., 2007).  The genotype files were 
searched for input errors, duplicates and missing data.  
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3.2.3.6  Analysis of Mild Malaria cohort genotype data 
The Mild Malaria Cohort database was merged with the validated genotype data 
(3.2.3.5) from the SNaPshot Multiplex assay for every gene respectively. Criteria for 
merging were the individual sample names (serial) that excluded the not genotyped 
samples of the original cohort.  
 
 
3.2.3.6.1  Poisson regression analysis 
The incidence rate (IR) is defined as the number of events (numerator) per person-
time units (denominator). It describes the rate that the event occurs in the population 
at risk. In the analysis of the Mild Malaria Cohort the presence of P. falciparum 
asexual parasites on thick blood smears from the patient with fever was defined as 
event.  
An established method to summarize incidence rates for multiple events with differ-
ent individual follow-up time is the Poisson regression (Frome et al., 1985). It as-
sumes the response variable has a Poisson distribution meaning that events occur 
in a fixed period of time and independently of the time since the last event. An ad-
vantage is its independence from normally distributed data. Additionally, it is capable 
to test for complex interactions with covariates.  
 
The Poisson regression model expresses the logarithm of the event rate as a linear 
function of predictor variables. 
In this model the incidence rate is defined for the j-th observation by: 
€ 
rj =eβ 0 +β1x1 +...+β kxk, j  
The expected number of events (
€ 
Ci ) and exposure (
€ 
Ei ) is calculated by: 
 
€ 
Ci =Eieβ 0 +β1x1 +...+β kxk, j = e ln(Ei )β 0 +β1x1,i +...+β kxk, j  
 
The incidence rate ratio (IRR) is obtained by comparing the IR between the geno-
type groups: 
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€ 
eβ i = e
ln(E )iβ 0 +β1 (x1 +1)+...+β kxk,i
e ln(E )iβ 0 +β1x1 +...+β kxk,i  
 
All following calculations were done in STATA v. 10.1 (STATA Corporation): 
Analogous to Wambua et al. (2006) the IRR and the effects of explanatory variables 
on incidence rate was estimated by Poisson regression for all SNPs in each gene. 
The follow-up cohort attrition bias was compensated using person-times for every 
individual. Additionally, several covariates were included to the analysis to test for 
interactions. Therefore, all genotypes and covariates were converted to indicator 
variables by the xi-option in STATA. Influence between covariates and genotypes 
were tested using the in STATA implemented xi-interaction expansion. Furthermore 
possible interactions of the genotypes with sickle cell trait (HbAS) were determined 
with the Wald test statistics. 
 
The unadjusted IRR was calculated. Additionally, in a second calculation the IRR 
was adjusted for covariates like age, sex, ethnic group, season of year, sickle-cell 
disease (HbAS) and α+–thalassaemia with the STATA xi-interaction expansions. 
Observations where the subjects were not available at the weekly monitoring were 
not included in the statistics.  
 
A goodness-of-fit-test was performed using the estat gof-option in STATA to validate 
the Poisson regression model for each result. Based on deviance statistics the Pois-
son regression model is inappropriate if the p-value of this test is significant. 
 
The relationships between the SNP genotypes and the log-transformed parasite 
densities in the Mild Malaria Cohort dataset were determined using linear regression 
analyses. When the dependent is a quantitative trait, linear regression is a adequate 
model for a association analysis in which a line is fit to the response in terms of the 
predictor’s count value and a p-value is computed for goodness of fit. 
 
For both analyses HbAS and α+-thalassaemia positive children were excluded due 
to association of both phenotypes on asexual falciparum parasite densities in the 
blood (Williams et al., 2005 2; Wambua et al., 2006). 
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In all calculations data of sickle cell genotypes from the Mild Malaria Cohort was 
used as a reference and positive control. The robust variance estimation option was 
used in un- and adjusted IRR calculations to account for potential clustering of 
multiple events within the same individuals (Lin and Wei, 1989).  
 
 
3.2.3.6.2  Multiple Failure-Time Analysis 
Failure-time analysis examines the relationship of the survival distribution to covari-
ates. Multiple failure-time analyses are widely used for time-to-failure data when 
multiple failures/ events were measured in the same subject. Like in the Poisson 
regression the presence of P. falciparum asexual parasites with fever was defined 
as failure. Hence the parasite infection could only have occurred one by one a 
method for ordered failure data was used. The Andersen-Gill model (Andersen and 
Gill, 1982) for multiple ordered failures analyses was performed. This approach 
measures time to first failure, time from previous to next failure and finally to the time 
point of observation dropout. Test of association was done with a Cox regression 
(Cox, 1972). It evaluates the effects of explanatory variables on the hazard rate 
using a proportional hazard regression model. The hazard rate reflects the proba-
bility of the event of interest happening in time and is defined for the jth subject in 
the data: 
€ 
hi(t | x j ) = h0(t)exp(x jβx )  
The regression coefficient 
€ 
βx  is estimated from the data and the baseline hazard 
€ 
h0(t)  is left unestimated. An advantage in this model is that no assumptions about 
the hazard over time have to be made. 
 
The calculated hazard rates are frequencies or probabilities that a failure occurs at a 
given time point and the hazard ratios were an estimation of the ratios of the hazard 
rate between the genotype groups. 
The validated data from the Mild Malaria Cohort was transformed into the required 
format of the Andersen-Gill model. For analysis all genotypes were converted in 
indicator variables by the xi-option in STATA. Again the robust variance estimator 
was used in regard of multiple measurements in the same individuals. 
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The in STATA v. 10.1 implemented Kaplan-Meier estimator was used to plot the 
failure function of the different genotypes from the multiple time-to-failure data. With 
every failure the subject is counted as lost but the subject re-enters immediately in 
the analysis until it finally drops out with its observation end. In all calculations sickle 
cell disease data was used as a reference. 
 
 
3.2.3.7  Power Calculation for the Severe Malaria Cohort genotyping 
Statistical power calculations inform and help to design case-control studies. They 
state the actual sample size needed to find a true genotype-phenotype correlation 
under the study specifications (Gordon and Finch, 2005). Additionally, they can help 
explaining possible causes for false or ambiguous results.  
To measure an effect of rs670 severe malaria power calculations were done with the 
Power for Genetic Association Analyses (PGA) software (Menashe et al., 2008). 
The program assumes that SNPs are biallelic and in Hardy-Weinberg equilibrium 
(HWE). It was used to determine the required number of genotyped cases and con-
trols to appoint the influence of rs670 genotypes in the Severe Malaria Cohort 
Study.  
 The threshold for the minimum sample size was set where the statistical power ex-
ceeded 0.8 and α 0.05 for association analysis. The power reflects the Type II error 
(β) that describes a false negative result. β is defined as 1-power. A false positive 
result is defined as type I error (α).  
The hazard ration calculated in the multiple failure-time analyses was used as rela-
tive risk (RR).  
 
 
3.2.3.9  Association analysis of rs670 in the Severe Malaria Cohort 
All validated rs670 genotype data from the RFLP assay (3.2.1.6) were validated 
(3.2.2.5) and were analyzed for association using χ2 –test, Fisher’s exact test and 
logistic regression. For all analyses the data was transformed into a binary dataset 
with children with past severe malaria events as 1 and children without as 0. 
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3.2.3.9.1 Association analysis of rs670 using χ2 – and Fisher’s exact test 
Both, the χ2 – and Fisher's exact test use contingency tables in the analysis. The  χ2 
–test calculates deviations from a  χ2 –distribution. If a variable equals the sum of the 
squares of a set of statistically independent standard Gaussian random variables it 
is in χ2 –distribution and the null hypothesis is true, meaning the observed equals the 
expected distribution. Contrary to χ2 –test the advantage of Fisher’s exact test is the 
independence of large sample sizes without relying on assumptions. For test of as-
sociation using allele frequncies the “gencc” command in STATA was used for cal-
culating odds ratios (OR) with Cornfield correction (Cornfield, 1956). Because of the 
large sample size when using alleles the Cornfield approximation is a better ap-
proach compared to the χ2 –test (Kung-Jong and Chii-Dean, 2003). 
 
 
3.2.3.9.2 Association analysis of rs670 using logistic regression 
The logistic regression calculates the prediction of the probability of occurrence of 
an event by fitting data to a logistic curve. It is a generalized linear model of a bi-
nomial regression model that predicts the probability of a binary event (e.g. sick or 
healthy) in relation between to one or more risk factors (e.g. age, ethnics) and an 
outcome. The logistic function is given by: 
€ 
P = 11+ e−z    
where P is the probability of the outcome and z is the exposure to risk factors that is 
defined by  
€ 
z = β0 + β1x1 + ...+ βk xk       
with β describing the coefficients of the variants of x1…xk. 
The odds are calculated by:      
€ 
odds = P1− P  .  
The odds ratio is calculated to compare the odds across groups. 
 
Logistic regression was used to test and adjust the association of rs670 alleles with 
severe malaria. The adjusted logistic model accounted for age, ethnic group, season 
of year, sickle-cell disease (HbAS) and α+–thalassaemia. Therefore, all covariates 
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were used with the x-expansion in STATA v. 10.1. For a higher statistical power the 
allele frequencies were used. 
 
 
3.2.3.10 Calculation of linkage disequilibrium and haplotype blocks  
Linkage Disequilibrium (LD) is the non-random association between bi-allelic alleles 
at two loci (Goldstein, 2001). All loci in LD are inherited together. The 4 possible 
gametes of two bi-allelic markers (A, B) in linkage equilibrium have a frequency (x) 
of:  
 A1B1       x11  
 A1B2       x12  
 A2B1       x21  
 A2B2       x22  
  
These frequencies can be calculated by their allele frequencies: 
 
 A1   p1 = x11 + x12   (x11= p1 q1) 
 A2   p2 = x21 + x22   (x21= p2 q1) 
 B1   q1 = x11 + x21   (x12= p1 q2) 
 B2   q2 = x12 + x22   (x22= p2 q2)  
 
If the 2 bi-allelic marker are in linkage disequilibrium a deviation in the expected and 
observed gamete frequencies can be calculated using:       D= x11x22 – x12x21  
D depends on allele frequencies so that changes in D reflect both changes in the 
intensity of the linkage correlation but as well changes in gene frequency. Therefore, 
LD is commonly measured by the ratio of D:    D' = D/Dmax  
where Dmax is the maximal possible value of D for the given allele frequencies (Le-
wontin, 1964). D’ ranging from 0 to 1, which 1 describes complete LD.  
 
Haplotypes are the combinations of alleles in a population. Loci in these blocks are 
in strong LD. The haplotypes were disrupted by mutation, genetic drift and/or re-
combination. These events causing a fragmentation of haplotypes that leads to hap-
lotype blocks (Gabriel et al., 2002). 
Conclusions about evolutionary history and/or selection in the genomic region can 
be made out of the block sizes and numbers. In a neutral model of molecular evolu-
tion (1.8) mutations and recombination events reduce the size of a haplotype thus 
older and relatively common alleles were found in small haplotype blocks. Young or 
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alleles influenced by selection will be associated in long-range blocks with a high 
frequency in the population (Bamshad and Woodding, 2003). In general, LD be-
tween two loci decreases more rapidly with increasing distance. The block size is 
influenced by varying recombination rates across the human genome with an aver-
age block length of 1-173kb (Gabriel et al., 2002).  
 
Genotype data in the PED file format were imported into the Haploview v.3.32 soft-
ware (Barret et al., 2005). Haplotype blocks were defined with the implemented 
variant of the algorithm developed by Wang et al. (2002) with a gamete frequency 
cut-off of 0.01. In this method the population frequencies of the 4 possible two-
marker haplotypes are computed for each marker pair. If all 4 possible haplotypes 
were observed, a recombination event occurred. A haplotype frequency cut-off of 
0.01 was used. Sequent markers formed haplotype blocks where only 3 gametes 
were observed. The LD is presented in the Haploview’s GOLD heatmap color 
scheme. 
 
Additionally, allele frequencies and the Hardy-Weinberg Equilibrium (HWE) were 
calculated. The frequency of a given genotype will reach equilibrium in a randomly 
mating population and will stay constant over many generations in the absence of 
selection, migration or mutation.  
 
HWE is defined by: p2+ 2pq + q2= 1 where p and q are the frequencies of the 2 al-
leles respectively. 
 
In several publications deviations from HWE were used as quality control for any 
DNA genotyping method and recommended as an essential part of any genome 
scan. Markers that are not in HWE should be excluded (Gomes et al.1999; Weiss et 
al., 2001; Xu et al., 2002). On the contrary Zou and Donner (2006) suggested the 
inclusion of these markers in further analyses. 
For Haploview’s implemented HWE calculation the observed was compared with the 
predicted heterozygosity in the cohort data. Latter was calculated with the minor 
allele frequency (MAF) using the equation:   
€ 
2 ×MAF × 1−MAF( ).  
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3.2.3.11 Reconstruction of haplotypes 
Haplotypes of the genotyped unrelated individuals in the Mild Malaria Cohort were 
reconstructed with the PHASE v. 2.1 software (Stephens et al., 2001, 2003). This 
software implements a model-based Bayesian method for estimating haplotypes 
from unrelated individual genotype data. This approach calculates the “best” recon-
struction haplotypes for each individual by an “approximate coalescent” model that 
reflects the fact that haplotypes in a population tend to group together in clusters of 
similar haplotypes. It assumes that the population has been evolving with a constant 
size for a long time and is randomly mating and that the locus under study is evolv-
ing neutrally (Stephens and Scheet, 2005). Besides the high accuracy in haplotype 
reconstruction its advantages lie in allowance for missing data strong and perform-
ance even when recombination occurred (Xu et al., 2004; Marchini et al., 2006; Li et 
al., 2007). 
For detection of signatures of recent selective sweeps in the target genes in the 
Sweep software (3.2.2.10.1) the genotyped data from the Mild Malaria Cohort was 
transformed into the format specified by the PHASE programme’s manual. SNPs 
that violated the HWE were excluded. 
PHASE v. 2.1 was run with the standard settings. For each individual only the haplo-
type combination with the highest probability was used for further analyses from the 
PHASE output file. 
 
 
3.2.3.12  Screening for signatures of recent selection 
For detecting signatures of recent selection in the genomic region of APOA1, 
FABP1 and SNAPAP  two different apporaches were used: 
  
 
3.2.3.12.1  Detection of extended haplotypes using Sweep software 
The Sweep software v. 1.0 (Sabeti et al., 2002) analyses haplotype structures in the 
genome to detect evidences of natural selection. It examines alleles in high fre-
quency in a haplotype with a long range LD across the genomic region. The decay 
of LD is a scale of the age the haplotype (1.8 and 3.2.2.8). It is measured by the 
extended haplotype homozygosity (EHH). The EHH is defined by the probability that 
two randomly chosen chromosomes carrying the core haplotype of interest are iden-
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tical by descent from the core over a genomic distance (Sabeti et al., 2002). For 
each allele, the haplotype homozygosity decays from 1 to 0 with increasing distance 
from the core.  
To visualize the LD decay from a core SNP haplotype bifurcation diagrams were 
calculated displaying the LD breakdown and splitting of the haplotypes from a de-
fined core SNP. This approach moves from the core SNP to the next marker and 
splits if two alleles are present.  
For determination of the LD decay in APOA1, FABP1 and SNAPAP only the calcu-
lated haplotypes of each individual with the highest probability were used (3.2.3.11). 
All haplotypes were arranged in the required format for the Sweep software like de-
scribed in the Sweep manual.  
 
 
3.2.3.12.2  Detection of signatures of selection using Haplotter software 
Haplotter, a web-based application developed by Voight et al. (2006), scans ge-
nomic regions for signs of selection in the phase I and II HapMap data (3.2.2.1). It 
calculates the integral of the decay of the EHH, a so called “integrated haplotype 
score” (iHS), away from the core allele until EHH reaches 0.05. iHS summed for the 
ancestral (iHHA) or derived allele (iHHD) over both directions away from the core 
SNP.  
The final iHS is obtained by: 
€ 
iHS = ln iHHAiHHD
 
 
 
 
 
  
An extreme positive iHS score (iHS > 2) means that haplotypes on the ancestral 
allele background are longer compared to derived allele background whereas an 
extreme negative iHS score (iHS < -2) means that the haplotypes on the derived 
allele background are longer compared to the haplotypes associated with the an-
cestral allele (Voight et al., 2006). 
This approach has the highest power to detect recent selection for alleles with me-
dium frequencies that have not reached fixation.  
The implemented gene-centered approach was used for APOA1, FABP1 and SNA-
PAP to calculate and visualize the iHS. Additionally, Haplotter’s implemented Fay 
and Wu's H (Fay and Wu, 2000) and Tajima's D (Tajima, 1989) were calculated to 
identify deviations in polymorphism frequencies due to selection. Both methods are 
based on the frequencies of the segregating polymorphisms in the genomic region 
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of interest. A positive or negative selection will shift the frequencies in different direc-
tions compared to the neutral model.  
Fay and Wu’s H is sensitive to high allele frequencies that exist due to a selective 
sweep. It compares the number of derived nucleotide variants at low and high fre-
quencies with the number of variants at intermediate frequencies (Bamshad and 
Wooding, 2003). This test requires knowledge of the ancestral allele (Sabeti et al., 
2006).  
An excess of low frequency alleles can be observed if these alleles are hitchhiking 
with the region under positive selection. Tajima’s D compares the number of ob-
served polymorphisms with the mean pairwise difference between sequences. Fay 
and Wu’s H and Tajima’s D have the greatest power to detect a selective sweep 
when the selected allele is fixed or close to fixation. In summary Fay and Wu’s H 
calculates departures from neutrality that are measured in the difference between 
high-frequency and intermediate-frequency alleles whereas Tajima’s D reflect the 
difference between low-frequency and intermediate frequency alleles thus predict 
departures from neutrality. Hence Tajima’s D is sensitive to population effects both 
tests combined can help to differ selection from population effects. Fay and Wu’s H 
is the most commonly used test for derived alleles (Sabeti et al., 2006). It is based 
on derived alleles thus knowledge of the ancestral alleles is required. In practice 
closely related species like chimpanzees are usually used as human ancestors. 
 
Because populations in different environments facing different selection pressures 
the allele frequencies in these populations should differ in the selected genomic re-
gions. The Wright Fixation Index FST can be used to measure the level differentiation 
between populations at a locus (Lewontin and Krakauer, 1973). It correlates the 
randomly chosen alleles within the same sub-population relative to its frequency in 
the entire population (Holsinger and Weir, 2009). It is an indicator to the degree of 
resemblance among individuals within populations and directly related to the vari-
ance in allele frequencies among populations (Holsinger and Weir, 2009). A small 
FST value indicates a similar allele frequencies within each population whereas 
large, it means different allele frequencies. In Haplotter the implemented FST statistic 
was used to compare the heterozygosity around the genomic region of APOA1, 
FABP1 and SNAPAP between the YRI and CEU population from the HapMap 
dataset. All these approaches can provide information about the evolutionary history 
of a genetic marker (Figure 5). 
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4.  Results 
 
4.1  Identification of SNPs in candidate genes APOA1, FABP1 and SNAPAP 
P. falciparum malaria has exerted strong selection pressure on the human genome 
for the last 10,000 years. In the context of high variability of individual disease out-
come the genetics of host response are likely to play an important role (Mackinnon 
et al, 2005). The protein UIS3 and UIS4 play an essential role in P. berghei liver cell 
stages. Mueller et al. could identify three host genes coding for liver ligands: 
APOA1, FABP1 and SNAPAP. I reasoned that if genetic polymorphisms in these 
three human candidates could alter host/parasite interactions children in endemic 
areas carrying protective alleles should be less susceptible to falciparum infections 
and suffer fewer malaria incidences. To address this question all three genes were 
screened for polymorphisms.   
 
 
4.1.1  Re-sequencing of APOA1 confirmed 11 SNPs 
I initiated my study by re-sequencing the genomic region around APOA1 
(ENSG00000118137) in 50 DNA samples from the area of Kilifi at the Kenyan 
Coast. They were randomly chosen and no anthropometric information was avail-
able. I sequenced every sample in 6 overlapping fragments spanning a genomic 
region of 2.5kb around APOA1 and re-aligned them using the BioEdit v. 7.0.9.0 
software. The APOA1 gene consists of 1.86kb and is located on Chromosome 11 at 
position 116,706,467 to 116,708,666. The open reading frame (ORF) is oriented to 
the opposite to the chromosomal direction that is annotated in the Ensembl data-
base. The gene consists of 4 exons and 3 introns. The Apolipoprotein A1 Precursor 
protein consists of around 243 amino acids (AS) with a molecular weight of 30kDa. 
Five different transcripts (mRNA) are annotated. 
In re-sequenced data I found 11 SNPs at the APOA1 locus. Two were identified in 
the 5’ UTR, another two in the 3’UTR whereas the remaining SNPs were scattered 
within the introns of the gene. In all 100 re-sequenced chromosomes no insertions 
or deletions were localized in this genomic region.  
 
All localized SNPs were indentified in the dbSNP database and named by the official 
identifier (Figure 7). The allele frequencies between the re-sequenced Kenyan sam-
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ples and data from the PharmGKB and CWRU Genomics databases were com-
pared. Latter consisted of sample data from Harare in Zimbabwe with 80 chromo-
somes and samples from 68 individuals from Michigan in the United States. The 
PharmGKB dataset contained a mix of samples from African-Americans and US-
Whites. No information about SNPs in the genomic region of APOA1 was available 
in HapMap Phase I or II data thus I could not compare frequencies between the 
populations from this database. 
For all 11 SNPs no information about function or effect was obtainable except for 
rs670 and rs5069. These two SNPs were associated with different phenotypes 
(Kamboh et al, 1999). SNP rs12718467 was excluded because of its low minor al-
lele frequency (MAF) of 1%. 
 
 
4.1.2  Selection of 11 SNPs and 2 tagSNPs in FABP1 by database screening 
For identification of SNPs in FABP1 and SNAPAP I screened the dbSNP, CWRU 
Genomics, PharmGKB, UCSC and the HapMap databases.  
The gene of FABP1 (ENSG00000163586) reaches from position 88,422,510 to 
88,427,635 on Chromosome 2. It consists of 4 exons and 3 large introns. Two tran-
scripts are coding for a small protein of 127 AS with a molecular weight of approxi-
mately 14kDa. SNPs were identified in the dbSNP and HapMap databases. Like 
APOA1 its ORF points to the opposite direction of the chromosome. I chose 10 
SNPs in the databases for the SNaPshot Multiplex assay (3.2.3.1). Their allele fre-
quencies from the HapMap datasbase in the Yoruba (YRI) population of Ibadan in 
Nigeria containing 30 sets of samples from two parents and an adult child were 
compared with the dataset of U.S. residents with northern and western European 
ancestry (CEU) by the Centre d'Etude du Polymorphisme Humain (CEPH) (Figure 
8). Latter consisted of thirty U.S. trios provided samples, which were collected in 
1980s.  
 
Here, allele frequencies from the YRI were compared with the CEU to identify SNPs 
that differ in frequency due to possible selection. All SNPs and their frequencies are 
listed in figure 8. No insertion or deletions were found in FABP1 using HapMap 
dataset according to McCarroll et al. (2006). 
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Tag SNPs obtain information about other SNPs without testing them directly be-
cause they are in high LD thus they minimize the number of SNPs in the assays. 
Usage of the HapMap dataset for tag SNPs in different populations was validated 
(De Bakker 2006). Therefore, I calculated two tag SNPs using the in HapMap im-
plemented Tagger (3.2.2.3). rs1545223 and rs1530273 were tagged by rs13399861 
and rs6711957 respectively. In both cases the tagging with a MAF cut off of 0.5 and 
r2 cut off of 0.8 was verified in the YRI and CEU HapMap dataset. All SNPs in 
FABP1 were distributed within the introns with unknown phenotype except for 
rs2241883. For the latter a shift from G to A results in a substitution from alanine to 
threonine that is associated with fasting triglycerides and LDL-cholesterol levels in 
females (Fisher et al., 2007). 
 
 
4.1.3  Selection of 12 SNPs in SNAPAP by database screening 
SNAPAP is located on chromosome 1 between position 153,631,145 and 
153,634,325. It is organized in 4 exons and 3 introns. The ORF is oriented in the 
same direction like the chromosome. Four transcripts are annotated in the Ensembl 
database. The protein consists of 136 AS with a relative molecular weight of 15kDa. 
Like in FABP1 I identified SNPs using database screening and compared their allele 
frequencies in the YRI and CEU datasets from HapMap. Again the SNPs were se-
lected according to their potential influence on gene function, known differences in 
allele frequencies between populations and the reliability of the primer in the SNaP-
shot Multiplex assay (3.2.3.4.2). 12 SNPs were selected for further genotyping (Fig-
ure 9). One SNP was located in the 5’UTR, three in the 3’UTR, four in the exons and 
another 4 in the introns. The allele change (AT) of rs1802461 leads to an AS ex-
change from serine to cysteine without known phenotype. Nucleotide substitutions in 
SNP rs16835479 and rs8532 result in a synonymous AS change. Like in FABP1 I 
found no insertions or deletion in SNAPAP using the HapMap data (McCarroll et al. 
2006). Furthermore, no tag SNP could be verified in the HapMap YRI or CEU 
dataset. 
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4.2  Genotyping of the Mild Malaria Cohort  
 
4.2.1  Genotyping Results of the Mild Malaria Cohort Study 
Due to the low amount of DNA in samples from the Mild Malaria Cohort I amplified 
728 sample genomes using the GenomiPhi Kit. This subset of the cohort contained 
duplicates or triplicates that were excluded from further analysis. All remaining sam-
ples were used for genotyping of the targeted SNPs in APOA1, FABP1 and SNA-
PAP with the SNaPshot Multiplex assay (3.2.1.8).  
The efficiency of the Long Range PCR (3.2.1.4.4.2) was proportional to the template 
product sizes of APOA1 (2.4kb), FABP1 (3.4kb) and SNAPAP (5kb). For this reason 
the obtained genotyped sample number for the APOA1 was highest followed by 
SNAPAP and finally FABP1. This was probably caused by progressing disintegra-
tion of the sample DNA due to the long-term storage and repeated freezing and 
thawing (Williams TN, personal communication). Using the Genemapper v. 4.0 soft-
ware all alleles were called automatically in the SNaPshot Multiplex assay. An ex-
ample of SNaPshot Multiplex electropherogram for each gene is displayed with its 
specific panel in Figure 10.  
 
Genotyping results of the SNaPshot Multiplex assays are presented in table 7,8 and 
9 for each tested gene, respectively. The SNPs are labelled with the dbSNP identi-
fier. In the 2nd column the alleles are shown with first the major and then the minor 
allele. The 3rd column gives the percentage of non-missing genotypes for this 
marker and the total number (n) of genotyped subjects. The minor allele frequency 
(MAF) is given in the 4th column. The major allele frequency can be calculated by 1-
MAF. For calculation of the Hardy-Weinberg equilibrium (HWE) the observed was 
compared with the predicted heterozygosity. Significant deviations were given by the 
p-value of HWE in the last column. I used HWE as quality control (Gomes et 
al.1999; Weiss et al., 2001; Xu et al., 2002). Contrary to these, markers that violated 
HWE were included tentatively in further analyses like proposed by Zou and Donner 
(2006). 
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b)
a)
c)
Figure 10:  Representative examples of SNaPshot Multiplex assay electropherograms for 
APOA1 (a), FABP1 (b) and SNAPAP (c)
In all three figures a representative example of the specific SNaPshot Multiplex assay is given with 
DNA (top) and without DNA (below). X-axes represent the run length in bp and the y-axes the 
fluorescence intensity. Grey boxes show the primer with coloured bins for the expected alleles in 
the panel (blue: G, green: A, yellow: C and red: T). Primers appear in order of table 4. Called 
alleles are listed below each electropherogram. An allele is only called if the peak emerges in the 
correct bin. Peaks appearing in the negative controls are smaller in presence of DNA due to 
exhaustion of the causal primers in the reaction. Heterozygous alleles are called in relation to their 
peak heights. Peak heights are influenced by amount of DNA and primer in the reaction and 
SNaPshot product loaded into the Genetic Analyzer.
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4.2.1.1  Alleles of 10 SNPs in APOA1 
For APOA1 568 samples from the Mild Malaria Cohort were genotyped (Table 7). All 
10 targeted SNPs were genotyped with an efficiency above 99%. No marker vio-
lated the HWE p-value threshold of 0.001. 
 
 
Table 7: Results of APOA1 genotyping in Mild Malaria Cohort with SNaPshot Multiplex 
assay 
 
dbSNP ID alleles 
non-missing 
alleles (%) / n 
MAF 
obs. 
HET 
pred. 
HET 
HWE 
p-value 
rs12718463 T:C 100 / 568) 0.34 0.42 0.44 0.31 
rs5081 T:A 100 / 568 0.27 0.37 0.39 0.39 
rs5076 G:A 99.8 / 567 0.15 0.18 0.25 0.002 
rs7116797 G:A 100 / 568 0.45 0.45 0.49 0.04 
rs5073 C:T 100 / 568 0.03 0.05 0.05 1.0 
rs5072 G:A 100 / 568 0.16 0.27 0.26 1.0 
rs2070665 G:A 100 / 568 0.17 0.30 0.29 0.25 
rs5070 A:G 99.8 / 567 0.42 0.44 0.48 0.06 
rs5069 G:A 100 / 568 0.20 0.30 0.32 0.20 
rs670 G:A 100 / 568 0.24 0.36 0.36 0.76 
 
 
 
4.2.1.2  Alleles of 11 SNPs in FABP1 
From the Mild Malaria Cohort 497 samples were genotyped for the 11 chosen SNPs 
in FABP1 (Table 8). Only 3 markers were below 100% of non-missing genotypes. 
The observed heterozygosity differed significantly from the predicted heterozygosity 
for marker rs2241883 and rs13399861 thus violated the HWE. 
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Table 8: Results of FABP1 genotyping in Mild Malaria Cohort with SNaPshot Multiplex 
assay 
 
dbSNP ID alleles 
non-missing al-
leles (%) / n 
MAF 
obs. 
HET 
pred. 
HET 
HWE 
p-value 
rs2197076 C:T 99.8 / 496 0.07 0.12 0.13 0.07 
rs11678114 C:T 100 / 497 0.03 0.06 0.06 1.0 
rs1545224 A:G 100 / 497 0.12 0.19 0.22 0.01 
rs1123605 G:A 99.6 / 495 0.003 0.006 0.006 1.0 
rs2241883 A:G 100 / 497 0.13 0.17 0.22 0.001 
rs6711957 C:T 100 / 497 0.39 0.43 0.47 0.0484 
rs13399861 C:T 100 / 497 0.39 0.56 0.47 0.00001 
rs28452712 G:A 100 / 497 0.34 0.44 0.45 0.76 
rs2919871 A:T 100 / 497 0.36 0.45 0.46 0.75 
rs7577401 T:C 99.8 / 496 0.03 0.07 0.07 0.95 
rs13400963 A:G 100 / 497 0.15 0.24 0.27 0.05 
 
 
 
 
4.2.1.3  Alleles of 12 SNPs in SNAPAP 
All 12 SNPs in SNAPAP were genotyped in 548 samples from the Mild Malaria Co-
hort (Table 9). Missing alleles were found in marker rs35903030, rs12742195 and 
rs7345. Marker rs16835479, rs16835479 and rs12742195 fell below the HWE p-
value threshold. SNP rs12742195 and rs12755522 were excluded due to low sized 
peaks and ambiguous allele calling in the electropherograms of the SNaPshot Multi-
plex assay. 
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Table 9: Results of SNAPAP genotyping in Mild Malaria Cohort with SNaPshot     
Multiplex assay 
 
dbSNP ID alleles 
non-missing 
alleles (%) / n 
MAF 
obs. 
HET 
pred. 
HET 
HWE 
p-value 
rs3806234 C:T 100 / 548 0.16 0.28 0.27 0.36 
rs35903030 G:C 99.8 / 547 0.001 0.002 0.002 1.0 
rs16835479 C:A 100 / 548 0.11 0.16 0.20 0.0001 
rs16835481 A:G 100 / 548 0.01 0.16 0.18 0.13 
rs8532 C:T 100 / 548 0.13 0.21 0.22 0.45 
rs6692298 G:C 100 / 548 0.35 0.21 0.46 1*10-32 
rs12742195 A:G 100 / 548 0.48 0.91 0.50 1*10-91 
rs12755522 G:T 100 / 548 0.002 0.004 0.004 1.0 
rs1802461 T:A 100 / 548 0.001 0.002 0.002 1.0 
rs16835489 A:C 100 / 548 0.01 0.03 0.03 1.0 
rs41305092 C:T 100 / 548 0.03 0.07 0.06 1.0 
rs7345 A:C 99.1 / 543 0.22 0.37 0.35 0.06 
 
 
 
4.3  Genotype-phenotype association analyses using single SNP approach 
Association studies based on SNPs are a widely used approach for identifying 
genes associated with diseases, pathomechanisms or phenotypes (e.g. body height, 
melanization) (Brooks, 1999). Here, I applied this approach to associate the pheno-
type, number of P. falciparum malaria events (presence of asexual blood stages 
with fever) in relation to the individual follow-up time, with the genotype in the Mild 
Malaria Cohort subset. Therefore, the validated genotype datasets from each gene 
were merged with the sample data from the Mild Malaria Cohort Study, respectively 
(3.2.3.6).  
Williams et al. (2005, 1) observed a decreasing protective effect of the sickle cell 
trait (HbAS) in children older than 10 years supposedly caused by an accelerated 
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immune acquisition of immunity. Accordingly, observations from subjects above 10 
years were excluded from analyses. For each gene the numbers of subjects and 
observations in the total and the reduced datasets containing only children younger 
than 10 years are listed in table 10. The distributions of observations by age are 
comparable between the three genes. Figure 11 exemplifies the distribution of ob-
servations by age groups for APOA1. 
 
 
Table 10: Number of subjects and observations from the genotyped Mild Malaria Co-
hort.  
The number of tested SNPs, subjects (n), malaria events and observations are listed for 
each gene in the total dataset and for children below 10 years. Additionally, the observations 
were translated into children years of follow-up (cyfu). 
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events cyfu n 
no. 
events 
no. 
obs. cyfu 
APOA1  10 568 86594 3047 1665 465 2767 70308 1352 
FABP1 11+2 497 74299 2633 1429 401 2345 59789 1150 
SNAPAP 10 548 82870 2862 1594 445 2574 67107 1291 
Figure 11: Frequency histogram of observations in the APOA1 dataset by 
months in children below 10 years. 
All observations from the genotyped Mild Malaria Cohort for APOA1 are pre-
sented by age in months. The height of the bars is equal to the number of obser-
vations in the age group thus the sum of the heights is equal to the total number 
of observations/ weekly visits. 
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4.3.1  Reduced risk in rs670 G carriers in Poisson regression analyses 
I used Poisson regression to determine the influence of the SNP genotypes and 
possible covariates on the incidence of P. falciparum malaria (3.2.3.6.1). Incidence 
rate ratios (IRR) were compared between the three possible genotypes of each 
SNP. Additionally, association was analysed in different age groups in each dataset 
to identify age-related associations.  
 
All SNP genotypes were tested for association with the occurrence of asexual para-
site blood stages in the cohort participants. Among all 33 finally used SNPs only 
rs670 (G/A) located in 5’ UTR of APOA1 was consistently associated with incidence 
and time to infection with P. falciparum. In analogy to HbAS (Williams et al., 2005, 
1), which I used as a positive control, the association depended on age of the sub-
jects in the cohort (Figure 12). Contrary to HbAS, association of rs670 was already 
lost in individuals older than 8 years. In both traits no association was observed in 
children younger than 12 months.  
In 306 non-immune children between 1 and 5 years, the most susceptible age 
group, rs670 was associated with P. falciparum incidence (p=0.003). In this age 
group I found an almost 50% lower risk of P. falciparum incidence in GG compared 
to AA carriers, reflected by the unadjusted median IRR of 0.52 (95% CI 0.34 - 0.80). 
Accounting for possible confounding variates I have found a similar IRR of 0.51 
(95% CI 0.32 - 0.84; p=0.007) in a separate Poisson regression model, which was 
adjusted for sex, age, season, location, ethnic group, HbAS and α+–thalassaemia. 
The effect of rs670 GG on P. falciparum incidence is comparable to HbAS. An un- 
and adjusted Poisson regression for HbAS showed an IRR of 0.59 (95% CI, 0.45-
0.78; p<0.001) and 0.60 (95% CI, 0.43-0.82; p=0.002), respectively. 
 
I accounted for a possibly inflated Type I error caused by multiple testing in a Pois-
son regression model in which all SNPs were included. The SNP rs670 remained 
significantly associated (unadjusted p=0.006; adjusted p=0.01) in 1-5 year old chil-
dren. The Poisson regression model for the association of rs670 was validated by a 
goodness-of-fit-test with a non-significant p-value of 1. 
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4.3.2  Multiple failure-time analysis revealed a prolonged time between infec-
tions by rs670  
An influence of rs670 on incidence of P. falciparum is probably caused by differ-
ences in time between infections. I used a multiple failure-time analysis based on 
the Anderson-Gill model for ordered multiple-failures to determine the time differ-
ences between P. falciparum infections and re-infections in relation to the SNP 
genotypes (3.2.3.6.2). 
Similar to the Poisson regression analyses an age-related effect of the rs670 geno-
types and time to P. falciparum infections was found. Again rs670 was significantly 
associated in the most susceptible age group from 1-5 years. In a Cox regression 
model a significant association from AA to GG was observed (p=0.005) in this age 
group. Analogous, this association was lost in children older than 8 years (p>0.05), 
contrary to HbAS, which remained significant (p<0.001). For both genetic traits I 
Figure 12: Incidence rate ratios for malaria of rs670 AA vs. GG and 
HbAA vs. HbAS by age 
The unadjusted IRR are presented for each age group. Below the children 
years of follow-up (cyfu) for each age group are listed. 
37335784 256 cyfu
34131668 239 cyfu
rs670
HbAS
rs670 GG
HbAS
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found no association in children below 12 months. The association strength of rs670 
GG and HbAS with time to infection was comparable with hazard ratios of 0.49 (95% 
CI, 0.29 – 0.81) and 0.55 (95% CI, 0.42 – 0.73), respectively.  
 
The time to detectable blood stage re-infections was extended by 63 days in GG 
carriers (median failure time of 126 days, 95% CI 98 - 154) compared to AA homo-
zygotes (median of 63 days; 95% CI 7 – 98). GA carriers had similar median failure 
times of 119 (95% CI 91 - 140) to GG homozygotes. This compares to a prolonged 
median time of 266 days in children with HbAS (95% CI 105 – 420) vs. children with 
normal HbAA (median 112 days, 95% CI 91 – 126). These results indicate a delay 
of detectable blood stages induced by both genetic traits. Times to-re-infection by 
genetic trait were graphed by Kaplan-Meier failure estimations for multiple failures in 
figure 13. One child carrying HbAS and the rs670 AA genotype showed a median 
survival time of 561 days suggesting dominance of HbAS thus it was excluded from 
the analyses.  
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Figure 13: Kaplan-Meier failure estimates in children 1-5 years by 
genotypic group 
Failure-time estimations are graphed for multiple failures in children by 
genotypes of rs670 and HbAS. Number of subjects (n), their total time at 
risk (days) and the incidence rate for the main genotypes are given in the 
box below graphs. 
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Using the cox regression analysis I could determine the influence of different factors 
on the variability in P. falciparum malaria incidence in children from 1 to 5 years. In 
total, all tested covariates (season, age, ethnic group, sex, location, α+–
thalassaemia, HbAS and rs670) explained 51% (95% CI, 46-60) of the variation. 
Broken down into the single variates (table 11) I found only three major factors influ-
encing incidence of P. falciparum. By far most of the variability is explained by the 
seasons underscoring exposure as a key factor of P. falciparum incidence. On the 
contrary host genetic factors seem to play a subordinate role on variability. rs670 or 
HbAS explained only 1.6% and 2%, respectively. 
 
 
Table 11: Covariates influencing variability in P. falciparum incidence in children 
1-5 years 
All variates are given with their explaining fraction and 95% CI on P. falciparum inci-
dence.  
factor explained variability 95% CI 
season 0.46   0.40   - 0.56 
age  0.001 <0.001 - 0.007 
ethnic group <0.001 <0.001 - 0.004 
sex <0.001 <0.001 - 0.007 
location  0.002 <0.001 - 0.009 
α+–thalassaemia <0.001 <0.001 - 0.007 
HbAS 0.02   0.006 - 0.038 
rs670   0.016   0.003 - 0.036 
total 0.51   0.40   - 0.60 
 
 
 
4.3.3  No association of rs670 with parasite density or epistasis with HbAS 
HbAS is affecting the development of intraerythrocytic P. falciparum stages. Wil-
liams et al. (2005, 2) described an association of HbAS on asexual parasites densi-
ties in the patient’s blood. Accordingly, determination of the influence of rs670 on P. 
falciparum blood stages could provide evidence to localize its effect. Therefore, I 
performed linear regression analyses with the rs670 genotypes and the P. falcipa-
rum parasite densities that were measured in the subjects from the Mild Malaria 
Cohort (3.2.3.6.1). Based on full blood count data the log10 transformed numbers of 
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P. falciparum asexual stages were used. In figure 12 the log numbers of parasites 
are plotted by the genotypes of rs670 and HbAS: In comparison the rs670 geno-
types show similar median parasite densities that do not differ significantly whereas 
the median number of parasites is considerably reduced in children with HbAS. As 
expected,HbAS was significantly associated with parasite densities in children be-
tween 1-5 years (p=0.001) whereas I found no association with rs670 (AA vs. GA: 
p=0.16 and AA vs. GG: p=0.28).  
 
 
 
 
 
 
 
 
 
 
 
Williams et al. (2005, 3) observed a negative epistasis between α+–thalassaemia 
and HbAS, both affecting P. falciparum erythrocytic stages. To detect possible inter-
action of rs670 and HbAS I examined the genotypes of both genetic traits using 
Wald statistical tests. A significant interaction between rs670 and HbAS was not 
observed (p>0.4). In summary both results indicate a spatial and/ or functional sepa-
ration between the effects of both genetic traits. In contrast to HbAS I found no evi-
dence that rs670 affects intra-erythrocytic development of P. falciparum or interacts 
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Figure 14: Dot plot of asexual P. falciparum parasites in children from 1-5 
years by rs670 (a) and HbAS (b) genotypes. 
The log parasite numbers of each subject were plotted by the genotype. Each dot 
stand for one observation thus the length represents the number. The median is 
marked in orange and the standard deviation in red. Subjects with HbAS or α+-
thalassaemia were excluded from the analysis of rs670 whereas α+-thalassaemia 
carriers were left out from the HbAS analysis. 
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with other protective traits against this parasite stage. On this account, an effect of 
rs670 on pre-erythrocytic P. falciparum parasites is the most likely explanation. 
 
 
4.4  Association of SNP rs670 with risk of severe malaria 
In the Mild Malaria Cohort an association of rs670 with P. falciparum infections and 
time to re-infection was observed. A possible influence on malaria pathology, mainly 
caused by blood stages, could not be tested. To this end I genoyped rs670 in a sec-
ond independent study group using a RFLP assay. This case-control study con-
sisted of subjects from the same but larger geographic area like the previous cohort 
(3.1.8.2). The study was designed to test for possible enrichment of rs670 alleles in 
children, who were admitted to Kilifi District Hospital with severe malaria, compared 
to the baseline prevalence in children without known severe malaria events.  
 
 
4.4.1  Power calculation for design of genotyping Severe Malaria Cohort 
In cohorts based on case-control designs it is helpful to calculate a benchmark of 
number of samples that is required to achieve sufficient statistical power. 
I used the Power for Genetic Association Analyses (PGA) software to obtain the 
required sample size from the Severe Malaria Cohort (3.2.3.7). The determined 
hazard ratio of 0.49 in children between 1-5 years (4.3.2) carrying the G was used 
as relative risk to calculate the minimum sample size for an association analysis. 
The control to case ratio was set to equal. For a statistical power of 0.8 and α of 0.5 
and using severe malaria disease prevalence of 0.02 and a frequency of the disease 
predisposing rs670 G allele of 0.76 I calculated a minimum sample size of 438 
cases and controls respectively. 
 
 
4.4.2  rs670 genotyping of the Severe Malaria Cohort 
For genotyping rs670 in a subset of the Severe Malaria Cohort I used an RFLP as-
say with the restriction endonuclease MspI (3.2.1.6). The digested PCR products 
were photographed and rs670 genotypes were determined manually for every indi-
vidual as exemplified in figure 15. All AA homozygous samples were confirmed in a 
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second repeated digestion to exclude a potential enzymatic failure in the first diges-
tion. 
 
 
 
In total I genotyped rs670 in 797 children with severe malaria and in 850 controls 
drawn from the population. Because of the strong influence of rs670 on P. falcipa-
rum infections in children below 5 all older subjects were excluded from further ana-
lyses. The rs670 genotype numbers of children with severe malaria events and con-
trols drawn from the population for the total Severe Malaria Cohort subset and for 
children below 5 years are listed in table 11. Again HWE was used for quality con-
trol. Testing for deviance I did not observe any violation of HWE in the total (p>0.5) 
as well in the two single datasets (p>0.5).  
 
 
Table 12: Distribution of rs670 in the genotyped Severe Malaria Cohort.  
The number of subjects (n) and genotypes of rs670 are listed for the total dataset and for 
children below 5 years. The sums of the subjects, genotypes or the average allele frequen-
cies are given in the last line. 
 
total <5 years  
n GG GA AA 
G
% 
A
% 
n GG GA AA 
G
% 
A
% 
sev. mal. 797 496 270 31 79 21 704 441 238 25 80 20 
controls 850 585 244 21 83 17 768 538 211 19 84 16 
sum/ ∅  1647 1081 514 52 81 19 1472 983 449 44 82 18 
 
250bp
100bp
150bp
Figure 15: Rs670 MspI RFLP assay 
PCR products were digested using MspI. The 
enzyme only cleaved if the G allele was 
present. At the top, the marker, the negative 
control and the genotypes of rs670 are listed. 
The AA genotype resulted in the 235bp PCR 
product. Heterozygotes showed the original 
and the two cleaved products with a length of 
135 and 100bp. In GG carriers only the 
cleaved products were left.  
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4.4.3  Lowered risk for severe malaria in rs670 G carriers 
In table 11 the differences in the rs670 allele frequencies between the children sug-
gest an enrichment of the A allele in children that suffered from severe malaria. A χ2 
–test using allele frequencies showed a significant association of rs670 with severe 
malaria (p=0.003). Calculation of an odds ratio (OR) of 0.75 (95% CI, 0.62-0.91) 
suggests a 33% lower risk to develop severe malaria for G allele carriers. Compar-
ing the three genotypes in a χ2 –test the association remained significant with a risk 
of 22% (p=0.01; Pearson χ2=9.29). This compares to children with HbAS that have a 
426% lower risk for severe malaria events (p<0.001). In table 12 the OR for the al-
leles and genotypes of rs670 and HbAS are listed. No differences were observed 
using Fisher’s exact test compared to the χ2 –test. 
 
 
Table 13: χ2 –test of rs670 genotypes in children <5 years. 
Number of cases and controls, their odds ratios with 95% CI obtained by χ2 –test are listed 
for rs670 and HbAS (without HbSS) as reference. The OR and CI of the alleles are obtained 
by Cornfields’ correction. 
 
 
 
Additionally, I used logistic regression analyses to account for possible confounding 
factors. Because of the low number of AA homozygotes I used allele frequencies to 
increase statistical power. In an unadjusted logistic regression model an OR of 0.75 
(95% CI, 0.60-0.90; p=0.003) for rs670 G carriers was observed, reconfirming the 
previous χ2 –test. Similar to previous comparison between genotypes, this effect was 
weaker to the well-established HBB S allele (OR 0.22, 95% CI 0.14-0.34; p<0.001). 
An adjustment for age, sampling location, ethnic group, HbAS and α+–thalassaemia 
allele/ genotype cases controls odds ratio 95% CI 
A 288 249 1.32 1.10 – 1.60 
G 1120 1287 0.75 0.62 – 0.90 
AA 25 19 1.32 0.72 - 2.38 
GA 238 211 1.13 0.93 - 1.36 
GG 441 538 0.82 0.72 - 0.93 
AA+GA 263 230 1.14 0.96 – 1.36 
HbAA 674 564 1.19 1.06 - 1.33 
HbAS 19 98 0.19 0.12 - 0.32 
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lowered the OR to 0.63 (95%, 0.47-0.90; p=0.009) for rs670 G whereas HBB S re-
mained at almost the same level (OR 0.20; 95% CI, 0.1-0.38; p<0.001). In Figure 16 
the unadjusted odds ratios of rs670 and HBB alleles are shown. It illustrates the 
weak effect of rs670 G on the odds to develop severe malaria compared to HBB S. 
The difference in strength of the effect suggests an influence of rs670 on pre-
erythrocytic P. falciparum stages in contrast to HbAS that directly affects develop-
ment of intra-erythrocytic stages. Again testing for epistasis between rs670 alleles 
with HBB S no interaction was found (p=0.8) using Wald statistics. HbAS and α+–
thalassaemia showed a borderline interaction (OR 3.7, 95% CI 0.95-14.9 p=0.06).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5  Screening for signatures of selection in APOA1, FABP1 and SNAPAP 
Malaria is the strongest known force for evolutionary selection in the recent history 
of the human genome (Kwiatkowski, 2005). Different signatures reveal old or recent 
selection events occurring in the human genome. They include skewed allele fre-
quencies between populations or conserved haplotypes. Here, I used different stat-
istical approaches to discover such signatures in the three targeted genes APOA1, 
FABP1 and SNAPAP. HbAS was used as reference. It is the best-described protec-
tive genetic trait against malaria. Despite the high and life-threatening morbidity in 
SS homozygotes its allelic frequency is elevated in malaria endemic regions.  
Figure 16: Odds ratio of rs670 and HBB alleles in children <5 years.  
Unadjusted OR are graphed with 95% CI by rs670 and HBB alleles. Numbers 
in brackets show the allele number in children with/ without severe malaria.  
 
HBB S (27/110)
rs670 G (1120/1287)
rs670 A (288/249)
HBB A (1367/1228)
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4.5.1  rs670 A allele is present at low to intermediate frequencies around the 
world  
Allele frequencies differ between populations as a result of random genetic drift or if 
they are under selection of local environmental factors. In the two study sites of the 
Mild Malaria Cohort, Chonyi and Ngerenya, rs670 genotypes are similar distributed 
with frequencies of 0.24, respectively (Figure 18). However, in the subset of the Se-
vere Malaria Cohort representing a larger geographic area, I found a lower A allele 
frequency of 0.17. This variation in frequencies is probably caused by the different 
ethnic composition between both sampled populations in the cohorts.  
In the combined data set of the total Mild Malaria Cohort and the children without 
severe malaria I calculated an A allele frequency of 0.2. I excluded the children with 
a past severe malaria event because of enrichment of the A allele due to its higher 
risk of severe malaria.  
Because of its association with different diseases rs670 was genotyped in many 
epidemiological studies. In Figure 14 I mapped these frequencies for different count-
ries around the world. Highest allele frequencies are found in central Asia with drop-
ping frequencies towards South-East Asia. American and European populations 
show a low to intermediate frequencies (0.1-0.19) whereas lowest frequency was 
observed in Nigeria. These results indicate a decrease in A allele frequency from 
east to west. In regard to the negative selection of the A allele by malaria Kenya 
(East Africa) could be the gateway between the high abundance of the A allele in 
Asia and low in Africa. 
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4.5.2  Haplotype blocks in APOA1, FABP1 and SNAPAP 
The linkage disequilibrium (LD) composition in APOA1, FABP1 and SNAPAP was 
examined to find signatures of selective events in the targeted genes. Haplotypes 
are the combinations of alleles in a population. Haplotypes can be disrupted by mu-
tation, genetic drift and/or recombination. Events causing a fragmentation of haplo-
types lead to haplotype blocks (Gabriel et al., 2002). The markers localized in these 
blocks are in linkage disequilibrium (LD), the non-random association of alleles at 
different sites. The size and number of these blocks show the evolutionary history of 
the genomic region.  
15%
France 3
11%
UK 1
19%
Italy 1
10%
Nigeria 4
18%
Northern
Brazil 2
(mixed pop.)
15%
Canada 1
16%
Japan 1
16%
Australia 1
Singapore 1
Chinese 30%
Malays   31%
Indians  20%
India 5,618%
U.S.A 1
(mixed pop.)
14%
Netherlands 1
17%
Denmark 1
Northern 22%
Tamilians 21%
China 7
Han        34%
Zhuang 30%
20%
Kenya
Figure 17: World map of rs670 A allele frequencies 
Allele frequencies of the minor rs670 A allele are given in percent for different populations 
(1: reviewed in Juo et al., 1999; 2: de Franca et al., 2005; 3: Helbecque et al., 2008; 4: 
Kamboh et al., 1999; 5: Chhabra et al., 2005; 6: Padmaja et al., 2009; 7: Li et al., 2008). 
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Figure 18: Distribution of rs670 genotypes in children 1-5 years from the Mild Malaria 
Cohort.
Genotpyes of rs670 are shown at the two study sites Chonyi and Ngerenya. Subjects from the 
Severe Malaria Cohort were sampled in the whole area of the DSS surveillance.
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Old and common mutations will be found in a smaller haplotype block than younger 
with lower frequencies. Patterns of LD and haplotype blocks can indicate signatures 
of recent selection (Nordborg et al., 2002). Between two haplotype blocks recombi-
nation events probably have occurred in the evolutionary history of the population 
(Wang et al., 2002). 
 
I calculated haplotype blocks from the Mild Malaria Cohort genotype datasets for the 
three genes with Haploview v. 4.1 software (3.2.3.10). The LD between the marker 
and calculated haplotype blocks are visualized in Figure 19: 
 
Around the genomic region of APOA1 all genotyped markers are in higher LD com-
pared to FABP1 and SNAPAP indicating a higher conservation in the evolutionary 
history of the population. However, only two haplotype blocks could be determined. 
One reaches out from the associated marker rs670 in the 5’UTR into the 1st intron 
with rs5069. The 2nd block ranges from marker rs5073 in the 3rd intron to rs5081 in 
the 3’UTR framing the 4th exon.  
 
Compared to APOA1 the LD between the tested markers of FABP1 is low. Two hap-
lotype blocks were calculated at both ends of the gene. In the 1st intron two markers 
(rs13400963 and rs7577401) forming a block. Despite the low LD (D’=0.01) only 
three of the 4 possible two-marker haplotypes are found above the frequency of 
0.01 thus it is unlikely that a recombination is deemed to have taken place. Another 
spans of 1kb spanned across the 3rd intron from marker rs1123605 to rs2197076. 
Again the LD within this block is low but in all combinations only 3 gametes were 
present.  
 
In general the genotyped markers in SNAPAP are in high LD. Especially marker 
rs35903030 in the 1st exon and marker rs1802461 in the 4th exon are in maximum 
LD (D’=1) with the other genotyped SNPs. Again two haplotype blocks could be 
identified: The first ranges from the 1st exon with marker rs35903030 across the 2nd 
exon to marker rs16835481 in the 2nd intron. The 2nd haplotype block is found from 
rs12755522 in the 3rd intron to the last tested marker rs7345 in the 3’UTR.  
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These LD patterns indicate a higher evolutionary conservation of APOA1 and SNA-
PAP than FABP1. Intriguingly in APOA1 and SNAPAP the 4th exon seems to be 
conserved. In FABP1 all markers close to the 4th exon are in LD indicating a conser-
vation of this region as well. The high LD in region of the 4th exon is possibly caused 
by essential coding sequences for protein functions.  
 
A reason for the observed LD patterns between these genes can probably be found 
in the different recombination rates between the three genes, calculated in the 
Hapmap Phase II data (Winckler et al., 2005; The International HapMap Consortium 
et al., 2007). The decay of LD, and thus the relative size of haplotype blocks, de-
pends on local recombination rates. In FABP1 and particular before the 3th exon 
recombination rates between rs13400963 and rs6711957 achieved 9 cM/ Mb mark-
ing this region as a recombination hot spot. Between rs2241883 and rs2197076 the 
recombination dropped to 1cM/ Mb, which was still almost ninefold higher compared 
to SNAPAP (0.12 cM/ Mb). Around APOA1 no recombination rates could be calcu-
lated due to the low number of genotyped SNPs in HapMap. 
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4.5.3 Haplotype analysis of rs670 revealed G as ancestral allele 
Under neutral evolution, new alleles require a long time to achieve high frequency in 
the population and recombination events will break down the LD in the genomic re-
gion (Sabeti et al., 2002). Accordingly, old and common alleles have only LD over a 
short distance on the chromosome whereas younger ones can have either long- or 
short-range LD. Haplotypes with high levels of haplotype homozygosity in combina-
tion with a high frequency in the population indicate evidence of recent positive se-
lection. 
 
To find signatures of selection, I examined the haplotype structures and distribution 
of rs670 by calculating individual haplotypes from all subjects of the Mild Malaria 
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Cohort. The bifurcation diagrams of haplotypes with the rs670 alleles as core SNP 
are visualized in figure 20 using SWEEP (3.2.3.12.1). 
The haplotypes containing the rs670 G allele are highly branched at each of the 10 
genotyped SNPs thus the haplotype frequencies are dropping to low frequencies 
with ongoing distance from the core. This fast decay of LD is not seen with the A 
allele as core SNP. Latter was highly abundant in a single major haplotype. From 
the core to the 7th marker (rs7116797) bifurcations with only low frequencies arise 
from every node. At marker rs5076 the major haplotype was splitted into two with 
comparable frequencies. In comparison, the low bifurcation rate of the A allele indi-
cate a conserved evolutionary history or recent appearance in population history. 
The G seems to be ancestral allele. The latter conclusion is supported by a G allele 
in that position in Chimpanzees, which are used as genetic ancestors to humans in 
the UCSC database. 
 
 
 
 
 
 
 
 
 
 
a) b)
Figure 20: Haplotype bifurcation diagrams of APOA1.  
The alleles G (a) or A (b) of rs670 are set as core SNP, indicated by a dark blue 
circle. Markers are ordered as seen in table 7. Moving from rs670 to the end of 
APOA1 each node represents a genotyped marker. The diagram divides if both al-
leles are present. The thickness of the lines corresponds to the number of samples 
carrying the haplotype.  
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4.5.4 No signatures of selection in the genomic region of APOA1, FABP1 and 
SNAPAP 
The genomic region around APOA1, FABP1 and SNAPAP were examined for signa-
tures of selection with the web-based Haplotter software. Applying the gene-
centered approach the iHS, Fay and Wu’s H, Tajima’s D and the Wright fixation in-
dex (FST) were calculated in 500kb of the proximal and distal genomic region from 
each gene, respectively. Each of theses statistical approaches provide information 
on different time scales in human history (Figure 5; Details: 3.2.3.12.2). Briefly, al-
leles under selection are embedded in extended haplotypes showing a high homo-
zygosity that can be measured using iHS statistics. Due to selection allele frequen-
cies can be skewed compared to the neutral model. This can be determined with 
Fay and Wu’s H and Tajima’s D. These tests differ in statistical power for detecting 
selection events and in their dependence on fixation of the marker in the population. 
 
For all calculations the HapMap Phase II dataset was used. Results of the statistical 
tests are graphed for HBB and APOA1 in Figure 21 and for FABP1 and SNAPAP in 
Figure 22. Here, only the CEU and YRI populations were compared in regard of 
different selection pressure from P. falciparum malaria. The East Asian (ASN) 
dataset was ignored due to fusion of Japanese individuals from Tokyo and Han Chi-
nese from Beijing (Voight et al., 2006). 
 
 
Around APOA1 no significant evidence of selection was observed in the two CEU 
and YRI datasets. The highest iHS of 0.6 was seen in the YRI population. In the 
vicinity of APOA1 the highest iHS peak was observed in the genomic region of the 
serine/threonine-protein kinase KIAA0999 at 200kb downstream of APOA1. A com-
parable result was observed with Fay and Wu’s H. The highest H value with 0.4 was 
measured in the CEU population suggesting low high frequencies of derived alleles 
thus objecting a selection event. Tajima’s D showed almost the same characterist-
ics. The highest value was observed in the CEU population of 1.75 whereas 1.25 
was measured in the YRI population. This indicates that APOA1 might not have ev-
olved neutrally in the CEU population. However, a comparison between the CEU 
and YRI populations with a FST of 1 showed a standard degree of population differ-
entiation. 
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In FABP1 no signatures of selection were observed in the CEU or YRI datasets. 
Both iHS scores of the CEU and YRI population reached the value of 0.3 indicating 
presence of only short haplotypes. Fay and Wu’s H and Tajima’s D showed no dif-
ferent frequency shifts from the neutral model in both populations. Both approaches 
had a maximum of 0.3 in the two populations. In almost the same manner the FST 
value reached only 0.3 indicating a shared evolutionary background of this locus in 
both populations. 
 
Like in APOA1 and FABP1 no high iHS score was observed in the genomic region 
of SNAPAP in CEU or YRI. The maximum value reached 0.6 in the CEU population. 
Also, Fay and Wu’s H and Tajima’s D showed no indication for a selective event in 
evolutionary history. The H score of 0.8 in the CEU was higher than in the YRI popu-
lation with 0.3. Tajima’s D score showed with 0.25 in CEU a slightly higher shift in 
allele frequencies than in YRI with 0.1. In both populations no signature of selection 
was observed compared with the FST statistics. The value of the CEU vs. YRI score 
showed a maximum of 0.25. 
 
For the HBB, which I used as reference, I also failed to find indications of long-range 
haplotypes in HBB due to a low iHS score of 0.5. The only significant iHS score in 
vicinity is the Olfactory receptor 51B2 (OR51B2) around 200kb upstream of HBB in 
YRI. Furthermore, the score of Fay and Wu’s H achieved only a low value of 0.1. 
Moreover, the low Tajima’s D score of 0.1 indicating normal heterozygosity in this 
genomic region. In comparison of both populations I found no significant difference 
between the YRI and CEU reflected by the low Fst score of 0.5. 
 
In summary I found no evidence of signatures of selection either in APOA1, FABP1 
and SNAPAP, or in HBB. In contrast to FABP1 and SNAPAP in which no selection 
is known, the absence of any signature of selection in APOA1 or at least HBB is 
surprising.  
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Figure  21: Screen for signatures of selection in HBB and APOA1
Graphs show score of iHS, Fay and Wu’s H, Tajima’s D and Fst in the genomic region of HBB (a,b,c,d) and 
APOA1 (e,f,g,h) in the CEU, YRI and ASN populations. Position of the gene (dotted line) is framed by 0.5Mb up- 
and downstream of the chromosome. Red blocks below x-axes represent genes in the genomic region.
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Figure  22: Screen for signatures of selection in FABP1 and SNAPAP
Graphs show score of iHS, Fay and Wu’s H, Tajima’s D and Fst in the genomic region of FABP1 (a,b,c,d) and 
SNAPAP (e,f,g,h) in the CEU, YRI and ASN populations. Position of the gene (dotted line) is framed by 0.5Mb up- 
and downstream of the chromosome. Red blocks below x-axes represent genes in the genomic region.
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4.6 Influence of APOA1 on P. berghei liver cell stage development 
The development of P. falciparum liver cell stages seems to be dependent on cho-
lesterol (Mikolajczak et al., 2007; Rodrigues et al. 2008). HDL and its major compo-
nent APOA1 is the key provider for cholesterol into the liver (Yalaoui et al., 2008). 
rs670 is associated with APOA1 expression but data from previous in vitro studies 
are contradictory (Tuteja et al. 1992; Agnotti et al. 1994). Therefore, I aimed to de-
termine the influence of APOA1 on the Plasmodium liver stage development di-
rectly. A previous knock-down of APOA1 using siRNA showed an impaired devel-
opment of P. berghei (Müller AK, personal communication). For testing the effect of 
an oversupply of APOA1 I performed experiments in transfected Huh7 hepatocytes, 
overexpressing rat APOA1, which were infected with P. berghei (3.2.2.5).  
 
First I aimed to measure the difference in development of P. berghei liver cell stages 
in WT and the transfected Huh7 hepatocytes. In parallel, the same experiment was 
performed in murine Hepa 1.6 hepatocytes.  A second experiment intended to quan-
tify the difference in growth in two transfected Huh7 cell lines: One overexpressing 
rat APOA1 and the other was transfected with a mock vector to account for the 
transfection. To measure differences in number and morphology of liver cell stages, 
they were stained by IFA (3.2.2.6.3). For quantification of P. berghei liver cells 
stages I used a real time PCR assay (3.2.2.6.2). 
 
 
4.6.1 IFA staining revealed increased size of P. berghei liver stages in APOA1 
overexpressing hepatocytes 
The liver cell stages were stained with anti-hsp70 antibody from mice and green-
fluorescent labelled anti-mouse antibody. The DNA from hepatocytes and parasites 
were stained with Hoechst. In the 1st experiment the wild type was compared to the 
transfected Huh7 cell line. This experiment was done once with duplicates for each 
cell line at three time points post invasion of P berghei. Because Hepa1.6 hepato-
cytes showed an impaired growth they were excluded from analyses.  
In Figure 23 the liver cell stage numbers were plotted for Huh7 hepatocytes at dif-
ferent time points post invasion (pi). At time point 24h pi the number of infected 
hepatocytes was around 30% higher in the WT compared to the transfected, APOA1 
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overexpressing Huh7 (ApoTrans). 48 hours pi the liver stages in the WT were re-
duced to the level of the ApoTrans cell line. The latter showed constant liver cells 
stage numbers suggesting appropriate growth conditions in contrast to WT. Last 
count was done on time point 60h pi. Here, I observed a drastic reduced number of 
liver cell stages in both cell line likely due to evasion of matured merosomes after 50 
hours post invasion. The remaining appeared to have a lagged development indi-
cated by their small size that was similar to 24h pi.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I determined differences in liver cell stage sizes of 50 liver cell stages (25 per dupli-
cate) at every time point and for each cell line. P. berghei liver cells stages were 
photographed and the green-fluorescent area of the parasite was measured 
(3.2.2.6.3). In Figure 23 all size measurements are displayed except from last time 
point of 60h pi.  
After 24 hours pi the liver stages of both cell lines showed a comparable mean cir-
cumferential area size whereas at time point 48h the means of the area size be-
tween the two cell lines differed. Although the sizes were highly variable I found  
significantly larger liver cell stages in the overexpressing APOA1 Huh7 compared to 
the wild type in an unpaired two-tailed Student t-test analysis (p<0.001). In compari-
Figure 23: Number of P. berghei liver cell stages in WT and ApoTrans. 
P. berghei liver cell stage numbers were counted at 24, 48 and 60 hours post invasion. 
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son the mean circumferential area was 25% bigger and their oval shape suggested 
a higher level of maturity in presence of high level of APOA1 (Figure 23 a,b). A 
Welch-corrected student t-test was used to account for significant variances of the 
standard deviations between the two cell lines (p<0.01). In contrast to 48h no sig-
nificant difference was observed between the both cell lines at 24h pi (p>0.5).  
In the second experiment using a Huh7, transfected with a different mock-vector, I 
could not confirm the results. Measuring the circumreferential area size no signifi-
cant difference between the mean sizes was observed (data not shown). The num-
ber of P. berghei liver cell stages between the two transfected cell lines did not dif-
fer. 
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Figure 24: Size of P. berghei liver cell stages in WT and ApoTrans. 
a,b: P. berghei liver cell stage sizes of WT (a) and ApoTrans (b) at 48h pi labelled with 
α-hsp70 (green) and with Hoechst stained DNA (blue). c: Size measurements are 
mapped at the Y-axis with a dimensionless circumferential areas size for WT and 
ApoTrans at 24 and 48h pi. Mean sizes are given by the dotted line. Error bars represent 
95% CI. 
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4.6.2 Quantification using real-time PCR indicates elevated Pb18s in APOA1 
overexpressing hepatocytes. 
 
For a quantification of P. berghei liver cells stages I used a real-time PCR assay. I 
aimed to measure the amount of Pb18s between infected cell lines at different time 
points post invasion using cDNA. Pb18s was normalised using host GAPDH as in-
ternal control to account for differences in isolation of RNA and amplification to 
cDNA between the samples (3.2.2.6.2). Expression of rat and host APOA1 was con-
trolled. 
For Hepa 1.6 and Huh7 the relative expression of Pb18s is graphed for each time 
point in Figure 25 (a,b). Each cell line was set into relation to the first measurement 
at time point 24h.  
In Huh7 and Hepa 1.6 the WT strain shows a decreasing expression of Pb18s at the 
subsequent time points. In the APOA1 overexpressing Hepa1.6 cell strain a maxi-
mum amount of Pb18s was observed at 48h pi, whereas in the transfected Huh7 
only a slight decrease of Pb18s was observed. At 60h the amount of Pb18s was 
reduced severely in all cell lines. However, the high variance within the ApoTrans 
and WT samples prevents any conclusions at this last time point. 
 
For comparing differences in growth between the WT and transfected cell lines each 
time point was set in relation to the WT at 24h pi. The results are graphed for 
Hepa1.6 and Huh7 in Figure 25 (c,d).  
Like in Figure 25 a,b the amount of Pb18s decreases from 24h to subsequent time 
points in the WT strains. In the transfected Hepa 1.6 a maximum of Pb18s was seen 
at 48h pi whereas it remained almost stable in the transfected Huh7. At the last time 
point of 60h pi the expression level was comparable between the transfected and 
the wild type strains. 
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Calculating the ratio of Pb18s between ApoTrans and WT strains at each time point 
I found a significantly elevated level in Huh7 (p=0.001) and Hepa 1.6 (p<0.001) at 
48h compared to 24h using a unpaired two-tailed Student t-test (Figure 26). In the 
transfected strains Pb18s was around 2.5 times higher compared to the WT at 48h 
pi. The quantity of Pb18s was similar between transfected and WT hepatocytes at 
24h or 60h pi. 
 
 
Figure 25: Pb18s in Huh7 (a,c) and Hepa 1.6 (b,d) cell lines at 24, 48 and 60 hours post 
invasion 
Amount of Pb18s in WT and transfected hepatocytes at 48h and 60h were related to 24h for 
Huh7 (a) and Hepa 1.6 (b). Below, Pb18s in Huh7 (c) and Hepa 1.6 (d) are set in relation to 
the specific WT at 24h. Error bars represent standard deviations. 
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In the second experiment designed to control for the transfection event I could not 
confirm these results. Quantification of Pb18s in the ApoTrans and the mock-
transfected strain showed no difference at any time point could be observed (data 
not shown). Both transefected cell lines differed in their duration of their cultivation. 
The mock-transfected cell linie, transfected shortly before the experiment, showed a 
decelerated growth compared to the ApoTrans cell line. 
 
In summary, I found a higher amount of Pb18s in the APOA1 overexpressing strains 
than in the WT indicating stable growth conditions in transfected Huh7 or even an 
increased growth of P. berghei in transfected Hepa 1.6 hepatocytes. The increase of 
Pb18s at 48h suggests an essential role of APOA1 for the development of liver cell 
stages at this time point. With regard to the finding of comparable numbers of liver 
cell stages but enlarged size the increase of Pb18s suggests a correlation of Pb18s 
to size or higher metabolic rate in P. berghei liver cell stages. However, a second 
experiment using a transfected cell line, which is not expressing rat APOA1 did not 
reinforce these results. The observed constrained growth of the mock-transfected 
Huh7 compared the ApoTrans could have been an explanation. 
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Figure 26: Pb18s ratio of ApoTrans/ WT in Huh7 and Hepa 1.6  
The mean ratio of Pb18s in Huh7 (a) and Hepa 1.6 (b) at 24, 48 and 60 hours post 
invasion is given by the dotted line. Error bars represent standard deviations. 
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5.  Discussion  
The recent detection of tolerance against artemisinine, the central components in 
current antimalarial combination drugs, underscores the vital need for new afford-
able drugs and innovative malaria intervention strategies (Dondorp et al., 2009). 
Critical to present malaria control efforts is the reduction of Plasmodium sporozoite 
transmission from mosquito to man. To date, the combination of validated interven-
tion tools, including vector control, exposure prophylaxis and an anti-sporozoite 
subunit vaccine, termed RTS,S/AS01, achieve significant reductions of sporozoite 
inoculations to the population at risk (Bejon et al., 2008). Ideally, these anti-
transmission strategies may be complemented by interventions that target the intra-
hepatic expansion phase of the malaria parasite before the onset of clinical symp-
toms, which are exclusively caused by asexual blood stage parasites (Hoffman and 
Doolan, 2000).  
Until to date, the roles of Plasmodium liver stage/ host interactions in malaria dis-
ease outcome remain unknown. After invasion of a suitable hepatocyte, the parasite 
resides within the parasitophorous vacuole (PV), which separates the parasite from 
the cytoplasm of the host cell (Labaied et al., 2007). Two parasite-encoded PV 
transmembrane proteins, termed “Up regulated in Sporozoites proteins 3 and 4” 
(UIS3 and UIS4) have been assigned an essential role in the development of the 
Plasmodium berghei liver stages (Müller et al., 2005 1,2). Yeast-Two-Hybrid screens 
of whole hepatocyte transcript libraries for factors discovered interactions of host 
ligands with the Plasmodium UIS4 and UIS3 proteins (Mueller et al., personal com-
munication). Apolipoprotein A1 (APOA1) and liver fatty acid binding protein 1 
(FABP1) were isolated as binding partners for UIS4 and UIS3, respectively. A third 
ligand called SNAP-associated protein (SNAPAP) was identified in P. berghei to 
interact with the UIS7 protein. In contrast to UIS3 and UIS4 no homolog of UIS7 is 
found in P. falciparum. 
 
In this thesis, I wanted to test whether human polymorphisms that alter the host-
parasite liver stage interactions, as exemplified by UIS4/APOA1, UIS3/FABP1 and 
UIS7/SNAPAP correlate with risk of natural infections in a malaria-endemic area. 
Accordingly, I genotyped and analysed single nucleotide polymorphisms (SNPs) in 
two independent well-characterised groups of children from the Kenyan coast (Wil-
liams et al., 2005 1,2,3; Wambua et al., 2006) using the cost-effective SNaPshot 
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primer extension assay with its high accuracy (Pati et al., 2003) and then deter-
mined their relationship with susceptibility to and outcome of P. falciparum infec-
tions. SNPs can be directly responsible for the observed phenotypes or be in linkage 
with the causal mutations. Genome wide approaches have been commonly used in 
European or Asian populations but they have been problematic in Africa due to the 
high ethnic diversity (Jallow et al., 2009). Candidate gene approaches have a high 
SNP resolution of the targeted genomic region but they are susceptible to false posi-
tive discoveries due to population structure (Altshuler et al., 2008). Here, I attempted 
to use information about ethnic groups in the cohort data for controlling for potential 
bias.  
 
Out of the 33 analyzed SNPs only rs670 (G/A) located in the 5’ untranslated region 
(UTR) of APOA1 was significantly associated with incidence and time to re-infection 
with P. falciparum. Interestingly, I did not find any association in FABP1, which is 
described to affect development of P. yoelii liver cell stages (Mikolajczak et al., 
2007). In contrast the lack of association with SNAPAP is unsurprising because P. 
falciparum does not appear to encode for a UIS7 homologue. 
 
Analogous to the fading protective effect of HbAS with increasing age (Williams et 
al., 2005 (1)), the association of rs670 appeared to vary with age of the patient, pos-
sibly due to maternally transmitted antibodies below one year of age and acquisition 
of malaria-specific immunity in individuals older than 8 years; although the effect of 
HbAS did not fade in the studied subset of the Mild Malaria Cohort. All further ana-
lyses concentrated on children from 1 to 5 years as the most susceptible age group 
for P. falciparum malaria. In this group protection against P. falciparum infections of 
almost 50% in children carrying the rs670 G allele was comparable to the effect of 
HbAS. This protective effect is most likely caused by the time differences between 
subsequent infections. In support of this notion, I observed a two-fold increase in 
time to infection in GG homozygotes when compared to AA allele carriers and half 
the time in children with HbAS in this age group. This observed effect of HbAS on 
time to re-infections was consistent with the findings in a longitudinal study of 225 
individuals in Mali (Crompton et al., 2008). The prolonged time until the parasites 
are detectable in the blood suggests a difference in development of parasites due to 
both genetic traits. 
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Because it is hardly possible to measure directly the P. falciparum infections in the 
liver of patients I used presence of asexual parasites in the blood as marker. For this 
reason I could not determine the direct influence of rs670 on liver cell stages. A de-
layed appearance of asexual blood stages could be explained by a slowed devel-
opment in the liver or an inhibited growth of intra-erythrocytic stages like described 
for HbAS (Pasvol et al., 1978, Kwiatkowski, 2005; Williams, 2006). In support for a 
liver stage-specific effect, the rs670 SNP does neither affect parasite blood stage 
parasite densities nor display epistasis with other blood-stage specific protective 
traits, e.g. α+-thalassaemia with HbAS, as it was observed for HbAS (Williams et al., 
2005, 1; Williams et al., 2005, 3). Multivariate analyses adjusted for potential con-
founding demonstrated independent protective effects for rs670 and HbAS, but not 
α+-thalassaemia. The latter showed no association on uncomplicated P. falciparum 
incidence or on parasitaemia as expected (Wambua et al., 2006). 
 
To minimize the risk of a false-positive association the effect of rs670 was confirmed 
in a second independent study group. Moreover, the risk to develop symptoms of 
severe malaria was evaluated. I observed 33% lower odds for developing severe 
malaria in children below 5 years carrying the G allele suggesting only a weak effect 
on disease outcome and thus likely no effect P. falciparum erythrocytic stages. This 
compares to the strong effect of the well-established HBB S allele influencing blood 
stage development.  
 
Because APOA1 is one of the best-known risk markers to coronary heart disease 
(Chhabra et al., 2005; McQueen et al., 2008) numerous studies of rs670 in different 
countries have been performed in the past. In many epidemiological studies the A 
allele was associated with a higher level of APOA1 and HDL but others could not 
confirm these observations. (Jenah et al., 1990; Xu et al, 1993; Needham et al., 
1994; Talmud et al., 1994; Wang et al, 1996; Kamboh et al; 1999). A systematic 
meta-analysis suggests an average increase of APOA1 plasma level by 5mg/dl in 
the A allele carriers (Juo et al., 1999).  
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Published reports of the effect of rs670 on a shifted expression of APOA1 in vitro 
are also contradictory. Some studies observed a link between APOA1 transcription 
and the A allele (Tuteja et al., 1992; Angotti et al., 1994) whereas other studies did 
not confirm these observations (Smith et al., 1992; Barre et al., 1994). Angotti et al. 
(1994) stated that elevated APOA1 serum levels are caused by a decreased binding 
affinity of an unidentified nuclear factor due to the A allele. Three transcriptional fac-
tors are described to bind in the region from -89 to -64 of APOA1. The hepatic nu-
clear factor 4 (HNF4) promotes whereas apolipoprotein regulatory protein 1 (ARP1) 
and Ear3/COUP-TF repress transcription of APOA1 (Lai et al., 2005). These find-
ings point to a complex regulation of the tandemly organized APOA1-APOC3-
APOA4-APOA5 gene cluster that is regulated in a multifactorial mode including the 
interaction of multiple genes and multiple environmental factors (Papazafiri et al., 
1991; Danek et al., 1998). 
 
Collectively, these studies support a change in APOA1 expression due to rs670. 
Accordingly, the most likely molecular interpretation of my epidemiological findings 
is a direct influence of reduced APOA1 expression levels due to the rs670 G allele 
on parasite development in the liver. Impairment of Plasmodium liver-stage devel-
opment is akin to the phenotype seen in wild-type mice infected with uis4(-)-
sporozoites (Mueller et al., 2005, 2). It was suggested that the fast development in 
the liver requires external lipids from the host (Mikolajczak et al., 2007). Rodrigues 
et al. (2008) showed that the depletion of all sources of cholesterol reduces infec-
tion, including liver cell stage development. An impaired development could result in 
a delay of release and/ or a reduced number of merosomes/ merozoites out of the 
liver into the blood.  
Both scenarios would explain the observed extended time to detectable blood 
stages in patients in the Mild Malaria Cohort. This is consistent with the weak effect 
of rs670 on severe malaria compared to HbAS. After the release of the parasites 
from the liver rs670 would have no influence on their growth in the blood in contrast 
to HbAS that act primarily on this stage (Williams et al., 2005). The higher risk of 
severe malaria due to the A allele could be caused by a accelerated development or 
high numbers of merosomes/ merozoites released from the liver resulting in a fast 
establishment of a detectable parasitaemia in the child.  
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Due to the complex regulation of the APOA1-APOC3-APOA4-APOA5 gene cluster 
and previous contradictory studies a direct measurement of the SNP on liver stage 
development in vitro was not reasonable. Supposing an impact of rs670 on APOA1 
expression I tested the influence of APOA1 on P. berghei hepatocyte stages in an 
overexpression model. In the human Huh7 and murine Hepa 1.6 hepatoma cell 
lines, overexpressing rat APOA1, the P. berghei liver cell stages were significantly 
larger and contained more 18s copies compared to the WT at 48h post invasion. 
The total number of hepatocyte stages was similar between both cell lines at this 
time point. A decrease of established liver cell stages from 24h to 48h in Huh7 WT 
indicates an increased invasion in these cells but suboptimal growing conditions for 
P. berghei. This pattern was observed before (Frischknecht F, personal communica-
tion). A higher 18s copy number suggests an increased number of merozoites per 
liver cell stage or an elevated metabolism which could result in healthier merozoites. 
The latter might be more successful in invading erythrocytes. 
However, in a second experiment using mock-transfected hepatoma cell lines, 
which were not expressing additional APOA1, instead of WT these results could not 
be reproduced. One reason could be the observed impaired growth of the mock-
transfected hepatocytes or a change in the composition of the growth media used in 
both experiments containing different quantities of external APOA1 concentrations 
(Pan-Biotech, personal communication).  
 
On a more general note, the use of promiscuous and fast growing P. berghei might 
be not representative with regard to human infections with P. falciparum. Reassur-
ingly, a knock-down screen using APOA1 siRNA showed an impaired development 
of P. berghei in vitro (Mueller AK, unpublished). Furthermore, P. berghei seems to 
have a delayed time to detectable blood stages in APOA1 knock-out mice (Mueller 
AK, personal communication). Furthermore, in knock-out and overexpression ex-
periments targeting the scavenger receptor BI (SR-BI) show comparable results to 
my first APOA1 overexpression experiment: In WT the liver cell stages were signifi-
cantly larger compared to SB-RI -/- mutants at 48h post invasion possibly due to lack 
of cholesterol. P. yoelli invasion in hepatocytes requires SR-BI as co-receptor to 
CD81 (Yalaoui et al., 2008). Besides the influence of SR-BI on hepatocyte permis-
siveness it is implicated in HDL uptake in hepatocytes (Rhainds and Brissette, 
2004).  
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The frequency of the beneficial HBB S allele in malaria-endemic areas is raised by 
positive selection pressure (Kwiatkowski, 2005; Williams et al., 2006), but the delet-
erious effects of HbSS on the health preclude its fixation in any given population. 
Despite a higher chance of severe malaria and thus a negative selective pressure 
the A allele frequency of 0.2 in my sample was more abundant than in the Nigerian 
population (0.1) (Kamboh et al, 1999) or in different European populations (0.1-0.19) 
(Siggurdson et al, 1992; Xu et al, 1994; Juo et al., 1999; Helbecque et al., 2008). 
However, its frequency is similar to South-East Asians (∼0.2) (Heng et al, 2001; 
Chhabra et al., 2005; Padmaja et al., 2009) and lower compared to the Chinese 
population (∼0.3) (Li et al., 2008). This pattern probably reflects the historical and 
ongoing immigration from East Asia to the East African Coast and mixing with the 
local population (Herzig and Pascale, 2006). The corresponding reduction of allele A 
frequencies further westwards could be caused by negative P. falciparum selection 
pressure.  
Interestingly, the A allele seems to be abundant in areas that are historically en-
demic for P. vivax. This non-lethal Plasmodium species causes morbidity and fewer 
severe complications (Breman, 2001, Mendis et al., 2001). It is hypothesized that in 
P. falciparum and P. vivax endemic areas infections with P. vivax that occur earlier 
in life could have a protective effect against later P. falciparum malaria (Maitland et 
al., 1996; Williams et al., 1996, Smith et al., 2001). Accordingly a permissive effect 
of rs670 A on P. vivax would result in a protective benefit in P. falciparum infection. 
 
As an alternative hypothesis I propose to also consider a similar beneficial effect in 
P. falciparum high-transmission areas. Gupta et al. (1999) observed low incidences 
of severe malaria in areas where transmission is highest. It is hypothesized that in-
fections in early infancy, when the children are protected by maternal antibodies, will 
quickly develop adaptive immune responses, which protect against severe malaria 
later in life. A considerable degree of immunity against the parasite is already 
achieved after 1 or 2 episodes of malaria (Gupta et al., 1999). An accelerated acqui-
sition of infections, as seen in rs670 AA homozygotes, during infancy would promote 
a fast acquisition of immunity during a time when the children are still passively pro-
tected by maternal antibodies. Contrary to high-transmission areas this effect would 
diminish in low-transmission areas.  
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APOA1 could also influence directly the immune response and acquisition of im-
munity. It may have a role in limiting inflammation (Bresnihan et al., 2004) and 
shows a negative correlation with TNF-α (Hyka et al., 2001). Furthermore, T-cells 
that are stimulated by APOA1-pretreated dendritic cells (DC) produced low levels of 
IFN-γ and APOA1 seems to inhibit cross talk between DC and natural killer cells 
(NK) (Kim et al., 2005). The latter, component of the innate immune system, induce 
apoptosis in infected cells whereas IFN-γ plays an important role in killing intra-
hepatocytic parasites by stimulating the production of nitric oxides by the infected 
hepatocytes (Oliveira et al., 2008). TNF-α is involved in regulation of immune cells 
and apoptotic cell death. Therefore, a reduction of IFN-γ and TNF-α caused by high 
level of APOA1 could increase the survival of Plasmodium liver cell stages. 
 
The genomic region around APOA1 is more conserved as indicated by higher LD 
between the SNPs compared to FABP1 and SNAPAP.  As described before, rs670 
was in LD with rs5069 that is thought to be relevant to APOA1 and HDL levels 
(Kamboh et al., 1996; Wang et al; 1996) but rs5069 was not associated to malaria 
incidence in my analyses. Because rs670 was not in LD with other associated SNPs 
close to APOA1 future studies should analyse the whole APOA1-APOC3-APOA4-
APOA5 gene cluster to identify all markers in LD with rs670 that might explain the 
inconsistent effect of rs670 in different ethnic groups.  
 
Interestingly, the association of rs670 with other diseases, especially coronary artery 
disease (CAD), indicate that the allele frequencies may be influenced by multiple 
factors (Chhabra et al., 2005; Vollbach et al., 2005; Dixit et al., 2007).  
 
While infectious pathogens, such as the malaria parasite, are the most likely driving 
forces for allelic frequencies in different populations, no signatures of selection on 
this locus or HBB in a population-genetic-based analysis of publicly accessible 
HapMap Phase II data was detected using Haplotter (Voight et al., 2006). Using dif-
ferent statistical approaches (iHs, Fay and Wu’s H, Tajima’s D and FST) I hoped to 
gain information about the evolutionary time point of a possible selectional event 
(Figure 5; Sabeti et al., 2006). None showed a significant signature of selection in 
APOA1, FABP1, SNAPAP or HBB. Only Tajima’s D in the CEU dataset indicated 
conserved region around APOA1 probably caused by its sensitivity to population 
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structures. These findings may be explained by mild selection pressure, reflected by 
low-odds ratio of rs670 against severe malaria. Population history could also be a 
factor: Mildly deleterious alleles can rise to moderate frequency in populations that 
have undergone recent expansion or neutral alleles might confer susceptibility to 
disease due to changes in living conditions like the burden of malaria accompanying 
human settlement (Altshuler et al., 2008). Additionally, rs670 could be prevented 
from fixation because of a balanced selection similar to HbAS (Williams et al. 2005, 
1). 
 
Alternative reasons, which would also explain the failure to pick up signatures of 
positive selection at the HBB locus, include the small sample sizes, the low SNP 
density, or absence of the relevant SNPs in the dataset. Especially in 40kb around 
APOA1 no SNP was genotyped in the YRI. Marker rs670 was missing in all dataset. 
This draws attention to the present limitations of the HapMap project and supporting 
the continued importance of candidate-gene association approaches. However, 
more studies will be required to confirm the described association of rs670 on P. 
falciparum malaria. Recent advances in sequencing technology and approaches, 
such as the 1000 Genomes Project, are promising new tools (Jallow et al., 2009). 
 
Collectively, my data suggests that polymorphisms, which protect against 
natural malaria transmission, exist. In my thesis I focussed on host cell proteins that 
upon infection are specifically recruited by the developing liver stage parasite. I in-
deed detected a robust protective effect of the SNP rs670 in the 5’ UTR of APOA1 
against both uncomplicated and severe malaria using two independent screening 
methods in malaria-endemic populations. Association of rs670 with the risk of P. 
falciparum re-infections and severe malaria emphasises the epidemiologically im-
portant role for protein-protein interactions at the pathogen/host interface. My candi-
date gene association gene approach can now be extended to host cell factors that 
play important roles in sporozoite invasion (Silvie et al., 2003, Rodrigues et al., 
2008, Yalaoui et al., 2008). Most importantly, my study is the first description of host 
cell polymorphisms that act specifically on the clinically silent malaria parasite ex-
pansion phase, a concept that may be extended to other human pathogens. My re-
sults also highlight the importance of lipid metabolism in host/pathogen interactions. 
Furthermore, it might provide a plausible explanation for the observed variations in 
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apolipoprotein, lipid levels and cardiovascular risk between ethnic groups (Kamboh 
et al., 1999; Mbalilaki et al., 2008; McQueen et al., 2008). It was shown that Asian 
Indians have considerably higher prevalence of premature coronary artery disease 
(CAD) and standardized mortality rates for CAD compared with Europeans, Chinese 
and Malays (Mohan et al., 2001). African blacks or Black Americans have a high 
prevalence of hypertension in association with coronary heart disease (Yanci, 2001; 
Marijon et al., 2007). It is implicated that genetic traits, such as rs670, have a strong 
influence on lipid composition besides cultural, social and environmental factors 
(Talmud et al., 1994, Shanker et al., 2008). In contrast to P. falciparum, the selec-
tional forces of late-onset diseases such as CAD are negligible. Therefore, genetic 
traits leading to cardiovascular diseases could be enriched in populations living in 
malaria-endemic regions due to a benefit from protection against P. falciparum. 
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Figure 27: Influence of rs670 on Plasmodium liver cell stages
This hypothetical model illustrates the effect of rs670 on liver cell stages. 
a: The rs670 A allele increases the amount of APOA1 decreasing IFN-! and TNF-" that results in 
a weak immune response against liver cell stages. The high level of available cholesterol stimu-
lates the development of the intra-hepatocytic parasites. Finally, a high number of merosomes 
and/or merozoites are released that rapidly establish a detectable blood infection. The optimal 
growth conditions could result in an accelerated maturation of liver cell stages and early release 
from the liver.  b: The rs670 G allele causes low level of APOA1 that reduces the amount of 
cholesterol leading to an impaired development of intra-hepatocytic parasites. The level of IFN-! 
and TNF-" are increased resulting in apoptosis of infected hepatocytes (X). As a result, low num-
bers of released merosomes and/or merozoites lead to a prolonged time to detectable asexual 
blood stages. The lack of cholesterol could result in delayed growth of liver cell stages and thus 
maturation to infective merozoites. 
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